Platinum-based photoinitiators and photocrosslinkers, their use in adduct formation
By reacting photolytic active platinum substances in platinum-based adducts with hydrogels or biomolecules, the problem of complex and insufficient stability of existing photoresponsive compounds is solved, and simplified manufacturing and production in biomedical applications is achieved. Highly efficient cross-linking and has antibacterial activity.
Patent Information
- Application Number
- CN202410541177.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-04-30
- Publication Date
- 2024-12-03
AI Technical Summary
The manufacturing process of existing photoresponsive compounds in biomedical applications is complex, lacking stability and efficient crosslinking, making it difficult to realize a simple and easy-to-use manufacturing method.
A platinum-based adduct has been developed, containing a photoly active platinum substance produced by a specific platinum (IV) complex, for use as a photoinitiator and a photocrosslinker to form platinum (I) radicals by UV radiation activation. React with hydrogel or biomolecules to form a platinum-based adduct with antibacterial activity.
The manufacturing of photoresponsive compounds in biomedical applications has been achieved, and their stability and cross-linking efficiency in hydrogel and protein labeling have antibacterial activities against E. coli.
Smart Images

Figure CN119060097A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to platinum-based adducts and methods for their preparation, such as, in particular but not exclusively, platinum-hydrogel or platinum-biomolecule adducts comprising a hydrogel or biomolecule to which a photolyzed active species of a platinum (IV) complex is attached. Background Art
[0002] Biomaterials play an important role in biomedical applications. In particular, polymer materials such as hydrogel-based materials and protein-based materials have attracted much attention and have been used in a wide range of biomedical applications such as skin scaffolds, drug delivery, medical imaging, tissue engineering, etc. However, it is believed that typical fabrications of the above materials, such as those involving photoresponsive compounds / molecules, may have disadvantages such as complex fabrication procedures, low cross-linking and / or labeling efficiency, etc.
[0003] In one example, when considering the manufacture of antimicrobial hydrogels such as antimicrobial gelatin, separate manufacturing steps may be required, including initial functionalization of gelatin with methacrylamide, followed by photocrosslinking of the modified peptides with a photoinitiator, and simultaneous or subsequent introduction of the antimicrobial agent. However, it is believed that antimicrobial agents, such as inorganic antimicrobial agents, particularly in the form of nanoparticles, may lack stability and dispersibility in hydrogels, which further increases the difficulty of manufacturing. Therefore, it should be appreciated that a simple, easy manufacturing method is rarely achieved.
[0004] In another example, it will be appreciated that many photoreactive protein labeling agents may involve carbene-enabled CH and NH insertion chemistries, which may suffer from low cross-linking efficiencies due to short-range species.
[0005] Therefore, there remains a strong need to provide new or otherwise improved photoresponsive compounds, such as photoinitiators and / or photocrosslinkers for use in the fabrication of biomaterials in biomedical applications. Summary of the invention
[0006] In a first aspect of the present invention, there is provided a platinum-based adduct comprising a substrate to which is attached a photolyzed active platinum species, the photolyzed active platinum species being generated from a platinum (IV) complex having a structure of formula (Ia):
[0007]
[0008] wherein X, X', Y, Y', R and R' are electron donor ligands; and n is zero, any positive charge or a negative charge. Optionally, at least one of the electron donor ligands comprises one or more of a nitrogen-containing ligand, an oxygen-containing ligand, a phosphorus-containing ligand, a sulfur-containing ligand or a halogen-containing ligand. Optionally, the photolyzed active platinum species comprises a platinum (I) radical.
[0009] In an optional embodiment, the platinum (IV) complex has the structure of Formula (Ib):
[0010]
[0011] in:
[0012] X, X', Y and Y' are independently selected from the group consisting of ammonia, halides, oxalates, diamines, dicarboxylates and glycolates,
[0013] R1 and R2 are independently selected from the group consisting of a linear or branched C1-C4 alkyl chain, a carboxyl group, and a carboxylate-containing group; and
[0014] n is zero charge.
[0015] Optionally, X and X' are linked to form a first bidentate ligand. Optionally, Y and Y' are linked to form a second bidentate ligand. Optionally, the substrate is hydrogel-based or biomolecule-based.
[0016] In optional embodiments, R1 and R2 are independently selected from the group consisting of: -CH3, -CH2CH3, -CH2CH2CH3, -CH2COOH, -CH2CH2COOH, -CH2COOCH3, -CH2CH2COOCH3 and -CH2COOCH2CH3.
[0017] In optional embodiments, X and X' are ammonia and / or chloride; the second bidentate ligand is a diamine; R1 and R2 are -CH3, -CH2CH2COOH, or -CH2CH2COOCH3; and n is zero charge.
[0018] In optional embodiments, Y and Y' are ammonia and / or chloride, the first bidentate ligand is cyclobutanedicarboxylate and / or oxalate, R1 and R2 are -CH3, -CH2CH2COOH or -CH2CH2COOCH3; and n is zero charge.
[0019] In one embodiment of the present invention, the platinum (IV) complex has the structure of Formula (IIa), Formula (IIb), Formula (IIc), Formula (IId), Formula (IIe), or Formula (IIf):
[0020]
[0021]
[0022]
[0023] Optionally, the platinum (IV) complex of formula (IIa) generates one or more of acetate radicals, cisplatin, chloride radicals, ROS and photolyzed active platinum species.
[0024] In optional embodiments, the chemical structure of the platinum (IV) complex remains unchanged in the absence of radiation for at least 30 min.
[0025] Optionally, the hydrogel substrate comprises any one of polyacrylamide or gelatin. In an embodiment of the present invention, the hydrogel substrate comprises any one of 10% acrylamide / bisacrylamide (29:1) and 5% gelatin.
[0026] Optionally, the biomolecule substrate comprises any of an amino acid or a polypeptide. In an embodiment of the present invention, the amino acid is selected from cysteine, methionine, tryptophan and tyrosine, and the polypeptide is BSA.
[0027] Optionally, the platinum (IV) complex further comprises a functional moiety attached to the platinum (IV) complex for functionalizing the platinum-based adduct. Optionally, the platinum (IV) complex has the structure of formula (IIIa):
[0028]
[0029] in:
[0030] X, X', Y, Y', R and R' are as defined above;
[0031] L is a linking group;
[0032] F is the functional moiety for functionalizing the platinum-based adduct; and
[0033] n' is zero, any positive charge, or any negative charge.
[0034] Optionally, the functional moiety has a reactive group that is complementary to the reactive group of the fluorescent reporter unit. In an optional embodiment, the platinum (IV) complex has the structure of formula (IIIb):
[0035]
[0036] in:
[0037] m is 1-6;
[0038] F is the functional moiety which is a bioorthogonal group selected from the group consisting of azide, terminal alkyne, activated cyclooctyne and tetrazine; and
[0039] n' is zero charge.
[0040] In an embodiment of the present invention, the platinum (IV) complex has the structure of formula (IV):
[0041]
[0042] In a second aspect of the present invention, there is provided a photoinitiator for hydrogelation, comprising a photolyzed active platinum species generated from a platinum (IV) complex having a structure of formula (Ia):
[0043]
[0044] wherein X, X', Y, Y', R and R' are electron donor ligands; and n is zero, any positive charge or a negative charge.
[0045] In an optional embodiment, the platinum (IV) complex has the structure of Formula (Ib):
[0046]
[0047] in:
[0048] X, X', Y and Y' are independently selected from the group consisting of ammonia, halides, oxalates, diamines, dicarboxylates and glycolates,
[0049] R1 and R2 are independently selected from the group consisting of a linear or branched C1-C4 alkyl chain, a carboxyl group, and a carboxylate-containing group; and
[0050] n is zero charge.
[0051] Optionally, 75% of the photolyzed active platinum species is retained after exposure to radiation.
[0052] In an embodiment of the present invention, the platinum (IV) complex has the structure of formula (IIa):
[0053]
[0054]
[0055] In a third aspect of the present invention, there is provided a photocrosslinker for hydrogelation or protein labeling, comprising a photolyzed active platinum species generated from a platinum (IV) complex having a structure of formula (Ia) or formula (IIIa):
[0056]
[0057] in:
[0058] X, X', Y, Y', R and R' are electron donor ligands;
[0059] L is a linking group;
[0060] F is a functional moiety for protein labeling; and
[0061] n and n' are each independently zero, any positive charge, or any negative charge.
[0062] In an optional embodiment, the platinum (IV) complex has the structure of Formula (Ib):
[0063]
[0064] in:
[0065] X, X', Y and Y' are independently selected from the group consisting of ammonia, halides, oxalates, diamines, dicarboxylates and glycolates,
[0066] R1 and R2 are independently selected from the group consisting of a linear or branched C1-C4 alkyl chain, a carboxyl group, and a carboxylate-containing group; and
[0067] n is zero charge.
[0068] In an embodiment of the present invention, the platinum (IV) complex has the structure of formula (IIa):
[0069]
[0070] In an optional embodiment, the platinum (IV) complex has the structure of formula (IIIb):
[0071]
[0072] in:
[0073] m is 1-6;
[0074] F is the functional moiety which is a bioorthogonal group selected from the group consisting of azide, terminal alkyne, activated cyclooctyne and tetrazine; and
[0075] n' is zero charge.
[0076] In an embodiment of the present invention, the platinum (IV) complex has the structure of formula (IV):
[0077]
[0078] In a fourth aspect of the present invention, there is provided an antimicrobial platinum-based adduct comprising a substrate to which is attached a photolytically active platinum species, the photolytically active platinum species being generated from a platinum (IV) complex having a structure of formula (IIa):
[0079]
[0080] Optionally, the substrate comprises polyacrylamide and the adduct has antibacterial activity against Escherichia coli (DH5α).
[0081] In the fifth aspect of the present invention, a method for preparing a platinum-based adduct according to the first aspect is provided, comprising the following steps: providing a solution mixture comprising a hydrogel precursor or a biomolecule and a platinum (IV) complex having a structure of formula (Ia); applying to the solution mixture a radiation of an amount and wavelength effective to activate the platinum (IV) complex to form a photolyzed active platinum species comprising platinum (I) radicals, the photolyzed active platinum species reacting with the hydrogel precursor or the biomolecule to form the platinum-based adduct.
[0082] Optionally, the radiation is UV radiation. Optionally, the UV radiation has a wavelength of about 360 nm to about 370 nm. Also optionally, the radiation is at about 9 mW / cm 2 to about 10mW / cm 2 UV radiation is applied at a power density of 1000 nm. BRIEF DESCRIPTION OF THE DRAWINGS
[0083] The invention will now be described in more detail, by way of example only, with reference to the accompanying drawings, in which:
[0084] Figure 1A is cisPt(IV)-1 (i.e., platinum(IV) complex of formula (IIa)) in DMSO-d6 1 HNMR spectrum;
[0085] Figure 1B is cisPt(IV)-1 in DMSO-d6 13 CNMR spectrum;
[0086] Figure 1C is cisPt(IV)-1 in DMSO-d6 195 PtNMR spectrum;
[0087] Figure 1D is the ESI-MS spectrum of cisPt(IV)-1;
[0088] Figure 1E is the HPLC chromatogram of cisPt(IV)-1;
[0089] Figure 2A is cisPt(IV)-2 (i.e., a platinum(IV) complex of formula (IIb)) in DMSO-d6 1 HNMR spectrum;
[0090] Figure 2B is cisPt(IV)-2 in DMSO-d6 13 CNMR spectrum;
[0091] Figure 2Cis cisPt(IV)-2 in DMSO-d6 195 PtNMR spectrum;
[0092] Figure 2D is the ESI-MS spectrum of cisPt(IV)-2;
[0093] Figure 2E is the HPLC chromatogram of cisPt(IV)-2;
[0094] Figure 3A is cisPt(IV)-3 (i.e., a platinum(IV) complex of formula (IIc)) in DMSO-d6 1 HNMR spectrum;
[0095] Figure 3B is cisPt(IV)-3 in DMSO-d6 13 CNMR spectrum;
[0096] Figure 3C is cisPt(IV)-3 in DMSO-d6 195 PtNMR spectrum;
[0097] Figure 3D is the ESI-MS spectrum of cisPt(IV)-3;
[0098] Figure 3E is the HPLC chromatogram of cisPt(IV)-3;
[0099] Figure 4A is carPt(IV) (i.e., a platinum(IV) complex of formula (IId)) in DMSO-d6 1 HNMR spectrum;
[0100] Figure 4B is carPt(IV) in DMSO-d6 13 CNMR spectrum;
[0101] Figure 4C is carPt(IV) in DMSO-d6 195 PtNMR spectrum;
[0102] Figure 4D is the ESI-MS spectrum of carPt(IV);
[0103] Figure 4E is the HPLC chromatogram of carPt(IV);
[0104] Figure 5A is oxaPt(IV) (i.e., a platinum(IV) complex of formula (IIe)) in DMSO-d61 HNMR spectrum;
[0105] Figure 5B is oxaPt(IV) in DMSO-d6 13 CNMR spectrum;
[0106] Figure 5C is oxaPt(IV) in DMSO-d6 195 PtNMR spectrum;
[0107] Figure 5D is the ESI-MS spectrum of oxaPt(IV);
[0108] Figure 5E is the HPLC chromatogram of oxaPt(IV);
[0109] Fig. 6A is transPt(IV) (i.e., a platinum(IV) complex of formula (IIf)) in DMSO-d6 1 HNMR spectrum;
[0110] Figure 6B is transPt(IV) in DMSO-d6 13 CNMR spectrum;
[0111] Figure 6C is transPt(IV) in DMSO-d6 195 PtNMR spectrum;
[0112] Fig.6D is the ESI-MS spectrum of transPt(IV);
[0113] Fig. 6E is the HPLC chromatogram of transPt(IV);
[0114] Fig. 7A is an alkyne-Pt(IV) (i.e., a platinum(IV) complex of formula (IV)) in DMSO-d6 1 HNMR spectrum;
[0115] Figure 7B is alkyne-Pt(IV) in DMSO-d6 13 CNMR spectrum.
[0116] Figure 7C is alkyne-Pt(IV) in DMSO-d6 195 PtNMR spectrum;
[0117] Fig.7D is the ESI-MS spectrum of alkyne-Pt(IV);
[0118] Fig. 7E is the HPLC chromatogram of alkyne-Pt(IV);
[0119] Fig. 8A is PC-1 in chloroform-d 1 HNMR spectrum;
[0120] Figure 8B is PC-1 in chloroform-d 13 CNMR spectrum;
[0121] Figure 8C is the ESI-MS spectrum of PC-1;
[0122] Fig.8D is the HPLC chromatogram of PC-1;
[0123] Fig. 9A is PC-2 in chloroform-d 1 HNMR spectrum;
[0124] Fig. 9B is PC-2 in chloroform-d 13 CNMR spectrum;
[0125] Fig. 9C is the ESI-MS spectrum of PC-2;
[0126] Fig.9D is the HPLC chromatogram of PC-2;
[0127] Fig. 10A is alkyne-Pt(II) in DMF-d7 1 HNMR spectrum;
[0128] Fig. 10B is alkyne-Pt(II) in DMF-d7 13 CNMR spectrum;
[0129] Fig. 10C is alkyne-Pt(II) in DMF-d7 195 PtNMR spectrum;
[0130] Fig. 10D is the ESI-MS spectrum of alkyne-Pt(II);
[0131] Fig.11 is a schematic diagram showing the chemical structures of the Pt(II) and Pt(IV) complexes disclosed in the present disclosure;
[0132] Fig.12 An LED light source (365 nm) used in the present disclosure is shown.
[0133] Fig.13A The results show that the irradiated and unirradiated (365 nm, 9.8 mW / cm 2 ) RP-HPLC (254 nm) chromatogram of cisPt(IV)-1 in water at 10 min;
[0134] Fig. 13B is the ESI-HRMS spectrum of cisPt(IV)-1, which shows cisplatin as the photolysis product of cisPt(IV)-1;
[0135] Fig.14 The photolysis products of cisPt(IV)-2 in water under UV (365 nm) irradiation are shown, characterized by HPLC (254 nm) and ESI-MS;
[0136] Fig.15 The photolysis products of cisPt(IV)-3 in water under UV (365 nm) irradiation are shown, characterized by HPLC (254 nm) and ESI-MS;
[0137] Fig.16 The photolysis products of carPt(IV) in water under UV (365 nm) irradiation are shown, characterized by HPLC (254 nm) and ESI-MS;
[0138] Fig.17 The photolysis products of oxaPt(IV) in water under UV (365 nm) irradiation are shown, characterized by HPLC (254 nm) and ESI-MS;
[0139] Fig.18 The photolysis products of transPt(IV) in water under UV (365 nm) irradiation are shown, characterized by HPLC (254 nm);
[0140] Fig.19 It shows that under irradiation (365nm, 9.8mW / cm 2 ) The percentage of intact Pt(II) and Pt(IV) complexes at 10 min;
[0141] Fig. 20A shows the photolysis of cisplatin in water by UV (365 nm) irradiation monitored by HPLC (254 nm);
[0142] Fig. 20B shows the photolysis of oxaliplatin in water by UV (365 nm) irradiation monitored by HPLC (254 nm);
[0143] Fig. 20Cshows the photolysis of carboplatin in water by UV (365 nm) irradiation monitored by HPLC (254 nm);
[0144] Fig.20D shows the photolysis of trans-platinum in water by UV (365 nm) irradiation monitored by HPLC (254 nm);
[0145] Fig.21A The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is the absorption spectrum of methylene blue aqueous solution;
[0146] Fig.21B The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is the absorption spectrum of methylene blue aqueous solution containing cisPt(IV)-1;
[0147] Fig. 21C The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is the absorption spectrum of methylene blue aqueous solution containing cisPt(IV)-2;
[0148] Fig.21D The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is the absorption spectrum of methylene blue aqueous solution containing cisPt(IV)-3;
[0149] Fig.21E The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is an absorption spectrum of a methylene blue aqueous solution containing cisplatin;
[0150] Fig.22A The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is the absorption spectrum of methylene blue aqueous solution;
[0151] Fig. 22B The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is the absorption spectrum of a methylene blue aqueous solution containing carPt(IV);
[0152] Fig. 22C The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is an absorption spectrum of an aqueous solution of methylene blue containing carboplatin;
[0153] Fig.23A The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is the absorption spectrum of methylene blue aqueous solution;
[0154] Fig. 23B The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is the absorption spectrum of a methylene blue aqueous solution containing oxaPt(IV);
[0155] Fig.23C The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is an absorption spectrum of an aqueous solution of methylene blue containing oxaliplatin;
[0156] Fig.24A The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is the absorption spectrum of methylene blue aqueous solution;
[0157] Fig. 24B The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is the absorption spectrum of a methylene blue aqueous solution containing transPt(IV);
[0158] Fig.24C The results show that the irradiation with and without UV irradiation (365 nm, 9.8 mW / cm 2 ) is an absorption spectrum of an aqueous solution of methylene blue containing reverse platinum;
[0159] Fig.25A The results show that the irradiation (365 nm, 9.8 mW / cm2) with or without DMPO is 2 RP-HPLC (254 nm) chromatogram of cisPt(IV)-1 at 8.9 min. The new peak at 8.9 min was characterized as the acetate radical spin adduct DMPO-Ac;
[0160] Fig.25B The results show that the TEMPO-induced 2 ) RP-HPLC (254 nm) chromatogram of cisPt(IV)-1;
[0161] Fig.25C The results show that the irradiation (365 nm, 9.8 mW / cm 2 ) in the case of RP-HPLC (254nm) chromatogram of DMPO;
[0162] Fig.25D The results show that the irradiation (365 nm, 9.8 mW / cm 2 RP-HPLC (254 nm) chromatogram of TEMPO in the case of )
[0163] Fig.26A The photostability of cisPt(IV)-1 in the presence of TEMPO in the dark is shown;
[0164] Fig.26B The photostability of cisPt(IV)-1 in the presence of DMPO in the dark is shown;
[0165] Fig.26C The photostability of cisPt(IV)-1 in the dark is shown;
[0166] Fig. 27 The photolysis of cisplatin in the presence of DMPO with or without acetic acid as monitored by HPLC (254 nm) is shown. Acetate radical-DMPO adduct (DMPO-Ac) is 1 HNMR characterization, as inserted 1 As shown in the HNMR spectrum;
[0167] Fig.28 is a schematic diagram illustrating the proposed mechanism of spin trapping of acetate radicals by DMPO during the photolysis of cisPt(IV)-1. Acetate radicals are formed during the photolysis of cisPt(IV)-1. In the presence of DMPO, a DMPO spin adduct, i.e., nitroxide, is formed, which is subsequently converted to its stable final product, nitrone;
[0168] Fig.29A The spin adduct of platinum radical and TEMPO, i.e. [Pt(NH3)2(TEMPO)Cl], in the photolysis of cisPt(IV)-1 is shown, characterized by ESI-HRMS (positive mode). A control experiment was also performed with cisplatin;
[0169] Fig.29B is a schematic diagram illustrating the proposed mechanism of spin trapping of platinum(I) radicals by TEMPO during the photolysis of cisPt(IV)-1;
[0170] Fig.29C Shown is the spin adduct of platinum radical with TEMPO, [Pt(NH3)2(TEMPO)OH], in the photolysis of cisPt(IV)-1 characterized by ESI-HRMS (positive mode).
[0171] Control experiments were also performed with cisplatin;
[0172] Fig.29D is a schematic diagram illustrating the proposed mechanism of spin trapping of platinum(I) radicals by TEMPO during the photolysis of cisPt(IV)-1;
[0173] Fig.30 shows the EPR spectrum of cisPt(IV)-1 in the presence of DMPO;
[0174] Fig.31A The UV / Vis absorption spectra of DPD (chlorine radical probe) in the photolysis of cisPt(IV)-1 are shown. A control experiment was performed with cisplatin;
[0175] Fig.31B The UV / Vis absorption spectra of TMB (ROS, hydroxyl radical probe) in the photolysis of cisPt(IV)-1 are shown. A control experiment was performed with cisplatin;
[0176] Fig.31C The UV / Vis absorption spectra of OPD (ROS, hydroxyl radical probe) in the photolysis of cisPt(IV)-1 are shown. A control experiment was performed with cisplatin;
[0177] Fig.32 shows the EPR spectrum of cisPt(IV)-1 in water containing TEMP upon irradiation, and a schematic diagram illustrating the proposed mechanism of radical quenching by TEMPO during the photolysis of cisPt(IV)-1;
[0178] Fig.33 shows the fluorescence spectra of DCFH used to monitor ROS generated in the photolysis of cisPt(IV)-1;
[0179] Fig.34A shows the fluorescence spectra of DCFH solutions containing cisPt(IV)-1 under normoxic and hypoxic conditions upon irradiation;
[0180] Fig.34B The extracted ion intensity (cisplatin: 300.9608) chromatogram of cisPt(IV)-1 solution upon irradiation monitored by LC-HRMS is shown. An unknown photolysis product was observed only under normoxic conditions, which has an m / z similar to cisplatin and has an isotopic distribution pattern containing platinum and chlorine elements;
[0181] Fig.35A is a photograph showing a yellow precipitate visually observed in a saturated cisPt(IV)-1 solution containing 1M DMPO.
[0182] Fig.35B yes Fig.35AThe ESI-HRMS spectrum of the yellow precipitate in the sample indicates that the yellow precipitate is cisplatin;
[0183] Fig.35C yes Fig.35A The HPLC chromatogram of the yellow precipitate in the embodiment of the present invention is characterized in that the yellow precipitate is cisplatin;
[0184] Fig.35D yes Fig.35A The yellow precipitate 1 HNMR spectrum, which is characterized in that the yellow precipitate is cisplatin;
[0185] Fig.36 shows the yield of cisplatin in the photolysis of cisPt(IV)-1 in the presence of different concentrations of DMPO monitored by LC-HRMS;
[0186] Fig.37A shows LC-HRMS chromatograms of different concentrations of cisplatin dissolved in water;
[0187] Fig.37B is a graph of peak area versus cisplatin concentration, showing the standard curve for cisplatin. Each point corresponds to Fig.37A The main ion intensity of cisplatin extracted by LC-HRMS [M+H] + :300.9608;
[0188] Fig.38A LC-HRMS chromatogram of cisPt(IV)-1 upon irradiation in the presence of DMPO is shown. Main ion intensity of extracted cisplatin [M+H] + :300.9608;
[0189] Fig.38B LC-HRMS chromatogram of cisPt(IV)-1 upon irradiation in the presence of TEMPO is shown. Main ion intensity of extracted cisplatin [M+H] + :300.9608;
[0190] Fig.38C The yield of cisplatin in the photolysis of cisPt(IV)-1 containing different concentrations of TEMPO quantified by a standard curve is shown;
[0191] Fig.39 It shows that under irradiation (365nm, 9.8mW / cm 2 ) in the presence and absence of DMPO or TEMPO;
[0192] Fig.40Ais the HPLC chromatogram (254 nm) of the photolysis of cisPt(IV)-1 in water upon irradiation;
[0193] Fig.40B is the HPLC chromatogram (254 nm) of the photolysis of cisPt(IV)-1 in water containing DMPO upon irradiation;
[0194] Fig.40C is the HPLC chromatogram (254 nm) of the photolysis of cisPt(IV)-1 in water containing TEMPO upon irradiation;
[0195] Fig.41 is a schematic diagram illustrating the proposed main photolysis mechanism of cisPt(IV)-1;
[0196] Fig.42 is a schematic diagram illustrating the photopolymerization of monomers using a Pt(IV) complex as a photoinitiator;
[0197] Fig.43 It shows that acrylamide containing cisPt(IV)-1 is irradiated (365nm, 9.8mW / cm 2 ) when the hydrogelation behavior;
[0198] Fig.44 is the SEM image of Pt-gel;
[0199] Fig.45A Shown are electrophoresis of protein markers, BSA, and A2780 cell lysate in the case of conventional APS / TEMED-Gel;
[0200] Fig.45B Electrophoresis of protein markers, BSA, and A2780 cell lysate in the context of Pt-gel is shown;
[0201] Fig.46 The release profile of platinum relative to the Pt-gel stent is shown;
[0202] Fig.47 Photographs of E. coli on LB agar plates treated with Pt-gel, I2959-gel, cisplatin, and PBS are shown;
[0203] Fig.48 The bacterial density of DH5α in LB liquid medium and Pt-gel co-culture is shown.
[0204] Fig.49A The positive ions and corresponding assignments of the adduct of cisPt(IV)-1 and cysteine upon irradiation observed by ESI-HRMS are shown;
[0205] Fig.49B The positive ions and corresponding assignments of the adduct of cisPt(IV)-1 and methionine upon irradiation observed by ESI-HRMS are shown;
[0206] Fig.49C The positive ions and corresponding assignments of the adduct of cisPt(IV)-1 and tryptophan upon irradiation observed by ESI-HRMS are shown;
[0207] Fig.49D The positive ions and corresponding assignments of the adduct of cisPt(IV)-1 and tyrosine upon irradiation observed by ESI-HRMS are shown;
[0208] Fig.50 The percentage of platinum bound to BSA is shown;
[0209] Fig.51 is a schematic diagram illustrating the hydrogelation of gelatin;
[0210] Fig.52 The results show that the irradiation (365 nm, 9.8 mW / cm 2 ) is a photo of Pt(IV)-gelatin hydrogel with a gelatin concentration of 5%. Pt(II) was also used as a control;
[0211] Fig.53A is a schematic diagram illustrating the design of a Pt(IV)-based photocrosslinker according to an embodiment of the present invention;
[0212] Fig.53B is a schematic diagram illustrating the chemical structure of a photocrosslinker disclosed in the present disclosure;
[0213] Fig.54A Shown are gel fluorescence (FL) and Coomassie blue (CBB) staining of photolabeled BSA by a Pt(IV)-based photocrosslinker;
[0214] Fig.54B Shows Fig.54A Quantification of the fluorescence intensity of the gel;
[0215] Fig.55A Time-resolved BSA labeling by switching light stimulation is shown;
[0216] Fig.55B Shows Fig.55A Pulse-chase labeled gel fluorescence (FL) and Coomassie blue (CBB) staining of BSA;
[0217] Fig.56 Synthesis Scheme 1 is shown, which summarizes the synthetic procedure of cisPt(IV)-1;
[0218] Fig.57 Synthesis Scheme 2 is shown, which summarizes the synthetic procedure of cisPt(IV)-2;
[0219] Fig.58 Synthetic Schemes 3A and 3B are shown, which summarize the synthetic procedures of cisPt(IV)-3 and MeSuc-NHS, respectively;
[0220] Fig.59 Synthesis Scheme 4 is shown, which summarizes the synthetic procedure of carPt(IV);
[0221] Fig.60 Synthesis Scheme 5 is shown, which summarizes the synthetic procedure of oxaPt(IV);
[0222] Fig.61 Synthesis Scheme 6 is shown, which summarizes the synthetic procedure of transPt(IV);
[0223] Fig.62 Synthetic Scheme 7 is shown, which summarizes the synthetic procedure of alkyne-Pt(IV);
[0224] Fig.63 Synthesis Scheme 8 is shown, which summarizes the synthetic procedure of PC-1;
[0225] Fig.64 Synthesis Scheme 9 is shown, which summarizes the synthesis procedure of PC-2; and
[0226] Fig.65 Synthetic Scheme 10 is shown, which summarizes the synthetic procedure for alkyne-Pt(II). DETAILED DESCRIPTION
[0227] As used herein, the forms "a", "an" and "the" are intended to include both the singular and the plural forms, unless the context clearly indicates otherwise.
[0228] The words "example" or "exemplary" used in the present invention are intended to be used as examples, instances or illustrations. Any aspect or design described as "exemplary" in this disclosure is not necessarily to be construed as being preferred or advantageous over other aspects or designs. Instead, the use of the words "example" or "exemplary" is intended to present concepts in a concrete way.
[0229] It is believed that the use of photolabile ligands to construct photoactivatable Pt(IV) complexes as prodrugs for chemotherapeutic applications has received much attention. Without being limited by theory, the inventors, through their own research, trials and experiments, have designed that Pt(IV) complexes can be used for biomedical applications, particularly by using Pt(IV) complexes having a Pt(II) anticancer drug core (such as cisplatin, carboplatin, oxaliplatin) and innocuous axial ligands such as acetate, succinate, succinate, etc. It has been found that Pt(IV) complexes can be readily photolyzed upon photoexcitation to produce various reactive free radical species that can form biomaterials (such as biochemical conjugates and / or biochemical adducts). Therefore, it should be understood that Pt(IV) complexes can be used as photoinitiators, photocrosslinkers and / or photoreactive labeling agents in various fields, including but not limited to chemical biology, medicinal chemistry, antitumor agents, etc.
[0230] According to the present invention, there is provided a platinum-based adduct comprising a substrate to which is attached a photolyzed active platinum species generated from a platinum (IV) complex (also referred to as a Pt (IV) complex).
[0231] As used herein, the term "substrate" refers to a molecule or chemical compound that provides a surface or three-dimensional (3D) space to which reagents can be added so that a chemical product can be produced by a chemical reaction. For example, in this embodiment, the Pt(IV) complex can produce a photolytic active platinum species, such as platinum(I) radicals, upon UV irradiation, and the radicals can react with the substrate to form a reactive adduct, particularly a Pt-substrate adduct, by, for example, polymerization (such as free radical polymerization), a cross-linking reaction, etc.
[0232] Depending on the nature of the substrate, the Pt-substrate adduct formed may be different. In one embodiment, the substrate may be a hydrogel substrate, such as polyacrylamide or gelatin. In another embodiment, the substrate may be a biomolecule substrate, such as an amino acid or a polypeptide. That is, in these embodiments, the Pt-substrate adduct may be any one of a Pt-polyacrylamide, a Pt-gelatin, a Pt-amino acid, or a Pt-protein adduct.
[0233] The Pt(IV) complex as described herein is in particular a photoactivatable Pt(IV) complex. As used herein, the term "photoactivatable Pt(IV) complex" refers to a platinum complex having a Pt core with an oxidation state of +4, and which complex can be activated by photolysis upon exposure to radiation, in particular UV radiation, to produce reactive species, in particular including reactive free radical species. In other words, Pt(IV) can be photoactivated upon UV radiation and produce photolytically active species, such as reactive free radical species including the mentioned platinum(I) radicals.
[0234] The platinum (IV) complex may have the structure of formula (Ia):
[0235]
[0236] wherein X, X', Y, Y', R and R' are electron donor ligands; and n is zero, any positive charge or a negative charge.
[0237] "Electron donor ligand" means an electron-donating ligand, i.e., a ligand having a donor atom (such as a nitrogen atom, an oxygen atom, a phosphorus (P) atom, or a sulfur atom) that can bring electrons. Examples may include nitrogen-containing ligands, oxygen-containing ligands, phosphorus-containing ligands, sulfur-containing ligands, and halogen-containing ligands. In particular, electron donor ligands may include, for example, imines, water, halide ions (i.e., halide ions, particularly chloride ions, bromide ions, or fluoride ions), amines, diamines, triamines, ammines (NH3), alkyls, cyano groups, nitro groups, hydroxyl groups, alkoxy groups, phenoxy groups, monoalkyl or polyalkyl anions, such as dicarboxylic acids such as oxalate or glycolic acid divalent anions, alcohol radical ligands, alkylthio groups, thiols, phosphates, phosphines, β-diketones, nitrate groups, heterocycles such as pyridine or 2-methylpyridine. As used herein, the term "alkyl" refers to a saturated straight or branched hydrocarbon, which may, for example, contain 1 to 20 carbon atoms, such as 1 to 5 carbon atoms.
[0238] In one embodiment, the platinum (IV) complex may have at least one of the nitrogen-containing ligands, oxygen-containing ligands, phosphorus-containing ligands, sulfur-containing ligands, or halogen-containing ligands as mentioned above.
[0239] In a specific embodiment, the platinum (IV) complex may have the structure of Formula (Ib):
[0240]
[0241] in:
[0242] X, X', Y and Y' are independently selected from the group consisting of ammonia, halides, oxalates, diamines, dicarboxylates and glycolates; R1 and R2 are independently selected from the group consisting of a straight or branched C1-C4 alkyl chain, a carboxyl group and a carboxylate-containing group; n is zero charge. The term "halide" generally refers to a halide ion, particularly including chloride, bromide or fluoride.
[0243] R1 and R2 are particularly independently selected from the group consisting of: -CH3, -CH2CH3, -CH2CH2CH3, -CH2COOH, -CH2CH2COOH, -CH2COOCH3, -CH2CH2COOCH3 and -CH2COOCH2CH3. That is, the innocent axial ligands of the Pt(IV) complex can be one of a carboxylic acid, succinic acid, adipic acid, a succinate or an adipic acid ester. It is believed that these ligands lack strong absorption at 365nm, thereby minimizing their competitive absorption of UV radiation at 365nm with the Pt core, thereby promoting the generation of reactive free radical species as mentioned herein by, for example, charge transfer (such as a ligand-metal charge transfer (LMCT) process). In a specific embodiment, R1 and R2 can be independently selected from the group consisting of: -CH3, -CH2CH2COOH or -CH2CH2COOCH3 and -CH2COOCH2CH3.
[0244] In one embodiment, X and X' can be linked to form a first bidentate ligand. In a specific embodiment, the first bidentate ligand can be cyclobutane dicarboxylate and / or oxalate, Y and Y' can be ammonia and / or chloride, R1 and R2 are -CH3, -CH2CH2COOH or -CH2CH2COOCH3; and n is zero charge.
[0245] In another embodiment, Y and Y' can be linked to form a second bidentate ligand. In a specific embodiment, the second bidentate ligand can be a diamine; X and X' can be ammonia and / or chloride, R1 and R2 are -CH3, -CH2CH2COOH or -CH2CH2COOCH3; and n is zero charge.
[0246] As a specific embodiment, the platinum (IV) complex has the structure of Formula (IIa), Formula (IIb), Formula (IIc), Formula (IId), Formula (IIe), or Formula (IIf):
[0247]
[0248]
[0249]
[0250] As described above, the Pt (IV) complex of the present invention can be photoactivated to produce reactive species in the presence of radiation, but the chemical properties remain unchanged in the absence of radiation. For example, in embodiments in which the Pt (IV) complex may include a cisplatin core (such as a platinum (IV) complex with formula (IIa)), the structure of the complex may remain unchanged for at least 30 min in the absence of radiation, but is arranged to produce one or more of acetate radicals, cisplatin, chlorine radicals, ROS and photolyzed active platinum species when photoexcited. In particular, the Pt (IV) complex with the structure of formula (IIa) can be excited to a transition state via ligand-metal charge transfer (LMCT). Then, each acetate ion ligand can provide an electron to the Pt (IV) center, resulting in homolysis of the Pt-O bond and subsequent reduction elimination, producing cisplatin and acetate radicals. The latter may further produce ROS in the presence of oxygen and water. These reactive radical species can then attack cisplatin, producing various active platinum species (including platinum (I)) and chlorine radicals.
[0251] As described above, the photolyzed active platinum species produced by the platinum (IV) complex will react with a substrate (such as a hydrogel-based or biomolecular substrate as defined herein) to form various Pt-based adducts. For example, in a specific embodiment in which the substrate is a polyacrylamide hydrogel substrate (such as a hydrogel substrate comprising 10% acrylamide / bisacrylamide (29:1)), the Pt (IV) complex can act as a photoinitiator to induce hydrogelation / polymerization of acrylamide and bisacrylamide by generating photolyzed active platinum species (such as platinum (I) radicals and / or other radical species as described herein), resulting in a Pt-gel adduct with a porous network and a uniform microstructure. Advantageously, it was found that the hydrogel adduct can retain at least about 75% of the photolyzed Pt species and has antibacterial activity against Escherichia coli (DH5α).
[0252] In another specific embodiment in which the hydrogel base is a gelatin hydrogel base (such as 5% gelatin), the Pt(IV) complex can act as a photocrosslinker to produce a gelatin hydrogel by generating a photolyzed active platinum species (such as platinum(I) radicals and / or other free radical species as described herein). In particular, the photolyzed Pt species can act as a photocrosslinker to directly produce a gelatin hydrogel (i.e., a Pt-gelatin adduct). That is, assuming that no additional (photo)crosslinkers and / or (photo)initiators are required, gelatin hydrogels can be prepared by easy synthesis.
[0253] In another specific embodiment, the Pt(IV) complex can act as a photoreactive labeling agent to produce Pt-amino acid adducts or Pt-protein adducts by generating photolyzed active platinum species (such as platinum(I) radicals and / or other radicals as described herein). In particular, the photolyzed Pt species can cross-link amino acids (such as cysteine, methionine, tryptophan, and tyrosine) or proteins (such as BSA) upon photoexcitation of the Pt(IV) complex.
[0254] In one embodiment, the platinum (IV) complex may further comprise a functional moiety attached to the platinum (IV) complex for functionalizing the platinum-based adduct. The platinum (IV) complex may, for example, have the structure of formula (IIIa):
[0255]
[0256] in:
[0257] X, X', Y, Y', R and R' are as defined herein;
[0258] L is a linking group;
[0259] F is the functional moiety for functionalizing the platinum-based adduct; and
[0260] n' is zero, any positive charge, or any negative charge.
[0261] As used herein, the term "functional moiety" refers to a functional moiety of a platinum (IV) complex that can allow the complex to add new functions, features and / or properties (i.e., functionalization) to a material such as a platinum-based adduct as mentioned herein. The functional moiety can be, for example, a reactive group that is complementary to a reactive group of another molecule, such as a chemical reporter molecule (e.g., a fluorescent reporter molecule / fluorophore, an MRI reporter molecule, etc.), a drug molecule, or a biomolecule (e.g., biotin, a peptide such as a cell penetrating peptide, etc.).
[0262] The linking group L is an organic unit of any length that comprises an atom or group that links (i.e., connects) two parts of the platinum (IV) complex, namely the 'platinum part' and the 'functional part' F of the platinum complex. Examples may include straight or branched alkanediyl or amide chains. In a specific embodiment of the present invention, L may be -(CH2) m The amide chain of CONH-, wherein m is an integer > 0, such as 1-6.
[0263] In a specific embodiment, the platinum (IV) complex may have a functional group having a reactive group that is complementary to the reactive group of the fluorescent reporter unit. The phrase "complementary" generally means that the reaction between the two reactive groups occurs in pairs, and such reaction will not occur without the presence of the other reactive group. Examples of such types may include redox reactions between reducing agents and oxidizing agents, bioorthogonal reactions, reactions between antibodies and antigens, and the like. The term "fluorescent reporter unit" or "fluorescent reporter molecule" refers to a fluorescent compound or molecule that emits radiation of a specific wavelength or a specific wavelength range upon light excitation, and can emit radiation of another wavelength and / or intensity upon reaction with the functional portion of the Pt (IV) complex, wherein such changes in emission wavelength and / or intensity can reflect the characteristics of the Pt (IV) complex, such as reaction rate, reaction yield / efficiency, and the like. Examples of fluorescent reporter units may include fluorescein, rhodamine, cyanine dyes, BODIPY dyes, and the like.
[0264] Preferably, the platinum (IV) complex may have the structure of formula (IIIb):
[0265]
[0266] in:
[0267] m is 1-6;
[0268] F is the functional moiety which is a bioorthogonal group selected from the group consisting of azide, terminal alkyne, activated cyclooctyne and tetrazine;
[0269] n' is zero charge.
[0270] In a specific embodiment, the platinum (IV) complex may have the structure of formula (IV):
[0271]
[0272] The following describes a method for preparing a platinum-based adduct. The method may include the following steps:
[0273] providing a solution mixture comprising a hydrogel precursor or a biomolecule and a platinum (IV) complex having a structure of formula (Ia) as defined herein; and
[0274] Radiation of an amount and wavelength effective to activate the platinum (IV) complex is applied to the solution mixture to form a photolyzed active platinum species comprising platinum (I) radicals, which reacts with the hydrogel precursor or the biomolecule to form the platinum-based adduct.
[0275] The hydrogel precursor can be prepared by providing a monomer solution. Optionally or additionally, the monomer solution may also include a crosslinking agent. For example, in an embodiment where the platinum-based adduct is a Pt-hydrogel adduct such as a Pt-polyacrylamide adduct, the hydrogel precursor can be a solution, such as an aqueous solution containing, for example, 10% acrylamide (i.e., monomer) and bisacrylamide (i.e., crosslinking agent) in a ratio of, for example, 29:1. In another exemplary embodiment where the Pt-based adduct is a Pt-gelatin adduct, the hydrogel precursor can be an aqueous solution of 5% gelatin (i.e., monomer).
[0276] In the embodiment where the platinum-based adduct is a Pt-biomolecule adduct such as a Pt-amino acid or a Pt-BSA adduct, the solution mixture may be a buffer solution such as a PBS solution at pH about 7.4 containing an amino acid or BSA. In particular, the method of this embodiment may further include a step of incubating the solution mixture in the dark at 37° C. for about 1 hour before performing a subsequent irradiation step.
[0277] The concentration of the platinum (IV) complex present in the solution mixture may vary according to actual needs. In particular, the concentration of the platinum (IV) complex may be about 10 μM to about 1000 μM.
[0278] After preparing the solution mixture, radiation having an effective wavelength and / or amount may be applied to the solution mixture to generate reactive free radical species as described herein. Preferably, the radiation is UV radiation, particularly UV radiation having a wavelength of about 360 nm to about 370 nm, such as about 365 nm. The radiation may be applied at about 9 mW / cm 2 to about 10mW / cm 2 , such as about 9.8 mW / cm 2 UV radiation is applied to the solution mixture at a power density of 100 Å.
[0279] UV radiation may be applied to the solution mixture for about 5 minutes to about 10 minutes, about 4 minutes to about 11 minutes, about 6 minutes to about 10 minutes, about 8 minutes to about 10 minutes, or particularly 10 minutes.
[0280] Optionally or additionally, the formed adduct may be isolated and / or washed with a suitable solvent. The expression "isolated" means that the Pt-based adduct is separated from the bulk reaction mixture / system, such as separating a Pt-hydrogel from a mold or container, precipitating a Pt-protein adduct from a reaction mixture, etc.
[0281] Another aspect of the present invention relates to a photoinitiator for hydrogelation comprising a photolyzed active platinum species generated from a platinum (IV) complex having the structure of formula (Ia):
[0282]
[0283] wherein X, X', Y, Y', R and R' are electron donor ligands as defined herein; and n is zero, any positive charge or a negative charge.
[0284] In one embodiment, the platinum (IV) complex has the structure of Formula (Ib):
[0285]
[0286] wherein X, X', Y and Y', R1, R2 and n are as defined herein.
[0287] In particular, as mentioned, in embodiments where the substrate is a hydrogel-based substrate, about 75% of the photolyzed active platinum species may remain in the adduct after exposure of the complex to radiation, such as UV radiation at about 365 nm.
[0288] As a specific embodiment, the platinum (IV) complex has the structure of formula (IIa):
[0289]
[0290] The present invention also relates to a photocrosslinker for hydrogelation or protein labeling, comprising a photolyzed active platinum species generated from a platinum (IV) complex having a structure of formula (Ia) or formula (IIIa):
[0291]
[0292] in:
[0293] X, X', Y, Y', R and R' are electron donor ligands as defined herein;
[0294] L is a linking group as defined herein;
[0295] F is a functional moiety for protein labeling; and
[0296] n and n' are each independently zero, any positive charge, or any negative charge.
[0297] In one embodiment, the platinum (IV) complex, particularly a platinum (IV) complex acting as a photocrosslinker for hydrogelation, may have the structure of Formula (Ib):
[0298]
[0299] wherein X, X', Y, Y', R1R2 and n are as defined herein.
[0300] As a specific embodiment, the platinum (IV) complex has the structure of formula (IIa):
[0301]
[0302]
[0303] In another embodiment, the platinum (IV) complex, particularly a platinum (IV) complex that acts as a photocrosslinker for protein labeling, may have the structure of formula (IIIb):
[0304]
[0305] in:
[0306] m is 1-6;
[0307] F is the functional moiety which is a bioorthogonal group selected from the group consisting of azide, terminal alkyne, activated cyclooctyne and tetrazine; and
[0308] n' is zero charge.
[0309] As a specific embodiment, the platinum (IV) complex has the structure of formula (IV):
[0310]
[0311]
[0312] The present invention also relates to antimicrobial platinum-based adducts comprising a substrate to which is attached a photolytically active platinum species generated from a platinum (IV) complex having the structure of formula (IIa):
[0313]
[0314] In an exemplary embodiment, the substrate may comprise polyacrylamide and the adduct may have antibacterial activity against Escherichia coli (DH5α), particularly when about 1 mM of a platinum (IV) complex is used to prepare the adduct.
[0315] Hereinafter, the present invention is described in more detail by way of Examples, but the present invention is not limited thereto.
[0316] Example
[0317] Materials, instruments, and reagents
[0318] Unless otherwise stated, all reactions were performed under normal atmospheric conditions and protected from light. All chemicals and solvents were purchased from commercial sources. Dulbecco's modified Eagle's medium (DMEM), minimum essential medium (MEM), Resveratrol Memorial Institute (RPMI) 1640 medium, trypsin, phosphate-buffered saline (PBS), and fetal bovine serum (FBS) were purchased from Life Technologies.
[0319] Unless otherwise stated, the light source was LED UV light (365 nm, 9.8 mW / cm 2 ). NMR data were recorded at room temperature in the dark using Bruker AVANCE III 300 MHz, 400 MHz and 600 MHz spectrometers. ESI-MS data were recorded using a liquid chromatography-mass spectrometer (API-3200 Triple-QMS / MS). High-resolution MS data were recorded using a Bruker Daltonics microTOF and a Sciex X500R Q-TOF.
[0320] The HPLC was carried out on a Shimadzu LC-20A HPLC instrument by Phenomenex 00G-4435-E0 Gemini 5 μm C18 HPLC analysis was performed on a 250 mm × 4.6 mm HPLC column. Samples were monitored by UV absorbance at 254 nm and ESI-HRMS in scan mode. Gradient elution was performed using solvent A (H2O) and solvent B (acetonitrile) at a flow rate of 1 mL / min. Samples were eluted using the following program: 0% B (0 min) - 100% B (9 min) - 100% (11 min) - 0% (12 min) - 0% (16 min).
[0321] The Pt content was measured by inductively coupled plasma optical emission spectrometry (ICP-OES) (PEOptima8000) or inductively coupled plasma mass spectrometry (ICP-MS) (PENexion2000). Gel fluorescence scanning was performed using Fujifilm FLA9000.
[0322] Methods and characterization
[0323] Photolysis of Pt complex
[0324] The photolysis of the Pt complex in the test tube was checked by reverse phase high performance liquid chromatography (RP-HPLC). 1 mM Pt complex was dissolved in water. The mixed solution was then irradiated with UV light (365 nm, 9.8 mW / cm 2) was irradiated for 10 min and the solution was checked by HPLC. The percentage of residual Pt complex was obtained from the ratio of the peak area of the Pt complex upon irradiation to the peak area of the intact Pt complex.
[0325] Free radical spin trapping assay
[0326] Water containing 1 mM cisPt(IV)-1 (Pt(IV) complex of formula (IIa)) and cisplatin was mixed with 1 or 10 mM DMPO or TEMPO. The mixed solution was irradiated with UV or kept in the dark for 10 min. The solution was analyzed by HPLC. The Pt(I) adduct was characterized by ESI-HRMS, and the acetate radical adduct was separated and characterized by proton NMR. To study the photolysis rate, the solution was irradiated with UV (365 nm, 9.8 mW / cm 2 ) were irradiated for 0.5, 1, 2, 3, 4, 5 and 10 min and analyzed by HPLC. To investigate the dark stability, the solutions were incubated in the dark at room temperature for 30 min and then checked by HPLC.
[0327] Electron paramagnetic resonance (EPR) analysis
[0328] The EPR spectra were recorded with an ADANISpinscanX spectrometer, running at 100kHz field modulation using a 150μT modulation amplitude. 5,5-Dimethyl-1-pyrroline N-oxide (DMPO) and 2,2,6,6-tetramethylpiperidine (TEMP) were selected as spin traps. Typically, 500mM DMPO or TEMP was mixed with 25mM cisPt(IV)-1 in water. The mixture was then irradiated with UV or kept at room temperature in the dark for 10min. The sample was transferred to a quartz capillary and the EPR spectra were recorded at room temperature.
[0329] Detection of reactive species by probes
[0330] 500 μM of Pt complex was mixed with 250 μM of free radical probes in H2O: N,N-diethyl-p-phenylenediamine (DPD) (for detecting chlorine free radicals), methylene blue (MB) (for detecting ROS, chlorine and hydroxyl free radicals), 2,3-diaminophenazine (OPD) (for detecting ROS and hydroxyl free radicals), 3,3',5,5'-tetramethylbenzidine (TMB) (for detecting ROS and hydroxyl free radicals). The mixture was irradiated with UV (365 nm, 9.8 mW / cm 2 ) irradiate for 10 min or keep in the dark. The absorbance of the probe is recorded by a plate reader.
[0331] Total ROS generation in solution detected by DCFH
[0332] 20 μL of dichlorodihydrofluorescein diacetate (DCFH2-DA) (1 mM) was added to 80 μL of sodium hydroxide aqueous solution (10 mM) and stirred at room temperature in the dark for 30 min to obtain DCFH2. Next, 400 μL of phosphate buffered saline (pH 7.4) was added to the mixture to obtain a DCFH2 solution (40 μM). 5 μM DCFH2 was then added to 50 μM Pt complex in PBS buffer, followed by UV irradiation for 10 min or kept in the dark. For hypoxia experiments, the complex solution was deoxygenated by injecting argon for 15 min. Fluorescence was monitored by a plate reader with an excitation wavelength of 450 nm and an emission wavelength of 490-700 nm.
[0333] Quantification of Cisplatin by LC-HRMS
[0334] 1 mM cisPt(IV)-1 was added to aqueous solutions of DMPO / TEMPO with different concentrations (0, 0.1, 1, 10, 50 / 100 mM). The mixture was illuminated with UV light (365 nm, 9.8 mW / cm 2 ) irradiation for 10 min. Afterwards, the solution was diluted several times and then analyzed by LC-HRMS. For hypoxia experiments, the complex solution was deoxygenated by injecting argon for 15 min. The main ion intensity of cisplatin at 300.9608 was selected for quantification, and the concentration of cisplatin was quantified by the peak area of the standard curve.
[0335] Gelation assay
[0336] Hydrogelation experiments were performed in glass vials. In a typical experiment, 100 μM of the platinum complex was added to a 10% acrylamide / bisacrylamide (29:1) aqueous solution. For hydrogelation with gelatin, 1 mM of the platinum complex was mixed with 5% gelatin in water. The mixture was illuminated at room temperature with 365 nm light (9.8 mW / cm 2 ) were irradiated for 10 min, and the formed hydrogel was tested by the vial inversion method.
[0337] For protein electrophoresis, 1 mM cisPt (IV) -1 was added to an aqueous solution of 10% acrylamide / bisacrylamide (29: 1), 375 mM Tris-HCl (pH 8.8) and 0.1% SDS. The mixture was irradiated at 365 nm for 10 min at room temperature to form a Pt-gel. Samples of 3 μL marker, 5 μg BSA and 20 μg A2780 cell lysate were loaded. After separation, the gel was stained with Coomassie blue and imaged by the ChemiDocTouch imaging system.
[0338] Antimicrobial assay
[0339] 100 μL of hydrogel (0.1% I2959 or 1 mM cisPt(IV)-1 + 10% acrylamide / bisacrylamide (29:1)) was prepared in a 96-well plate. The mixture was irradiated (365 nm, 9.8 mW / cm 2 ) for 20 min and washed twice with PBS. 20 μL of DH5α (about 9×10 7 CFU / mL) of PBS solution was added to the gel surface. At the same time, PBS containing 100μM cisplatin or pure PBS was used for control. After incubation at 37°C for 4 hours, the sample was washed twice with 100μL PBS. PBS was combined to collect surviving bacteria and further diluted 10,000 times. Then 20μL of bacterial PBS solution was evenly spread on a 10cm agar plate and incubated at 37°C for 18 hours, and then imaged by the ChemiDocTouch imaging system. In LB medium, in the absence or presence of Pt-gel treated with DH5α, the optical density OD600 was also monitored every half hour with a microplate reader.
[0340] Release profile of platinum from Pt-Gel
[0341] 500 μL Pt-gel was prepared by mixing 10% acrylamide / bisacrylamide (29:1) and 1 mM cisPt(IV)-1 in water and irradiated with UV for 10 min in a 48-well plate. The Pt was washed with 1 mL PBS and transferred to a 15 mL tube. 5 mL PBS was added and the mixture was incubated at 37°C with gentle shaking. 200 μL of supernatant was taken at a given time point. The Pt concentration was determined by ICP-OES.
[0342] BSA binding
[0343] 5mg / mL BSA was mixed with Pt complex (final Pt concentration = 50μM) in PBS (pH7.4) buffer. The mixture was incubated at 37°C for one hour and then irradiated with UV or kept in the dark at room temperature for 10min. Afterwards, acetone was added to the solution and kept at -20°C for one hour to precipitate. The protein precipitate was collected by centrifugation (14,000rpm, 10min at 4°C) and resuspended in PBS buffer. The binding content of Pt was determined by ICP-OES.
[0344] In vitro BSA photolabeling
[0345] PBS (pH 7.4) buffer containing 3 mg / mL BSA was treated with 10 μM (0.1% DMF) of different compounds. The mixture was incubated at 37°C for 1 hour and then UV irradiated (365 nm, 9.8 mW / cm 2 )5min. The reactants were then quenched by adding acetone and stored at -20°C for one hour. The precipitated protein precipitate was then collected by centrifugation (14,000rpm, 10min at 4°C). The samples were dissolved in PBS and fresh premixed click chemistry reaction mixture (100μM TBTA, 1mM CuSO4, 1mM TCEP and 50μM TAMRA-N3) was subsequently added. The reactants were incubated at ambient temperature for one hour and then quenched with SDS-PAGE loading buffer. The labeled proteins were separated by SDS-PAGE and visualized by in-gel fluorescence scanning.
[0346] For time tracking analysis of the reaction, PBS containing 3 mg / mL BSA was treated with 10 μM (0.1% DMF) of Pt(IV)-based photocrosslinker. 50 μL aliquots were taken every two minutes and precipitated with acetone. At given time points (5, 11 and 17 min), the reaction mixture was irradiated with UV for 30 s. The precipitated protein pellet was dissolved in PBS and analyzed by in-gel fluorescence scanning as described above.
[0347] Example 1A
[0348] Synthesis of cisPt(IV)-1 (Pt(IV) complex of formula (IIa))
[0349] The synthesis of cisPt(IV)-1 is summarized in Fig.56 (Scheme 1). The complex cisPt(IV)-2OH was synthesized according to the reported method. 400 mg cisPt(IV)-2OH was suspended in 12 mL anhydrous DMF. 170 μL acetic anhydride was added. The reactants were stirred at room temperature for 24 hours. The solvent was removed by vacuum. The solid was washed with acetone and Et2O and dried in vacuum to obtain the product. 1 HNMR(600MHz,DMSO-d6)δ6.53(t,J=47.8Hz,6H),1.91(s,6H)( Figure 1A ). 13 CNMR(151MHz,DMSO-d6)δ178.68,23.35. ( Figure 1B ) 195 Pt NMR(129MHz,DMSO-d6)δ1231.67( Figure 1C ). ESI-HRMS (positive mode) m / z: C4H 13[M+H] of Cl2N2O4Pt + Calculated value: 418.9874, measured value: 418.9873( Figure 1D The HCLP chromatogram of the obtained cis-Pt(IV)-1 showed a single peak, indicating the high purity of the complex ( Figure 1E ).
[0350] Example 1B
[0351] Synthesis of cisPt(IV)-2 (Pt(IV) complex of formula (IIb))
[0352] The synthesis of cisPt(IV)-2 is summarized in Fig.57 (Scheme 2). 200 mg of cisPt(IV)-2OH and 216 mg of succinic anhydride were mixed in a 50 mL round bottom flask. The mixture was dissolved in 1.5 mL of DMSO and further stirred at 80 ° C for 3 hours. Then 5 mL of acetone was added, followed by precipitation with 35 mL of Et2O. The solid was collected and washed with Et2O, and finally vacuum dried. 1 HNMR(600MHz,DMSO-d6)δ12.08(s,2H),6.48(s,6H),2.50–2.47(m,4H),2.37(t,J=7.1Hz,4H)( Figure 2A ). 13 CNMR(151MHz,DMSO-d6)δ180.02,174.23,30.92,30.28( Figure 2B ). 195 PtNMR(129MHz,DMSO-d6)δ1228.63( Figure 2C ). ESI-HRMS (positive mode) m / z: C8H 17 [M+H] of Cl2N2O8Pt + Calculated value: 534.9986, measured value: 534.9993( Figure 2D The HCLP chromatogram of the obtained cis-Pt(IV)-2 showed a single peak, indicating the high purity of the complex ( Figure 2E ).
[0353] Example 1C
[0354] Synthesis of cisPt(IV)-3 (Pt(IV) complex of formula (IIc))
[0355] The synthesis of cisPt(IV)-3 is summarized in Fig.58 As shown in the top (Scheme 3A), the synthesis of cisPt(IV)-3 involves the reaction of cisPt(IV)-Ac with MeSuc-NHS. Fig.58 Preparation shown at bottom (Scheme 3B).
[0356] Specifically, 610 mg NHS and 1035 mg EDCI were added to a solution of 500 mg monomethyl succinate in 35 mL DCM. The reaction mixture was stirred at room temperature for 6 hours and quenched by adding water. The organic phase was washed twice with brine. The product was obtained by removing the solvent in vacuo and was used directly without further purification.
[0357] The complex cisPt(IV)-Ac was synthesized according to the reported method. Then, 122 mg of MeSuc-NHS was added to a solution of 200 mg of cisPt(IV)-Ac in 2 mL of DMSO. The reaction mixture was stirred at 45°C overnight. The desired product was purified by HPLC. 1 HNMR(600MHz,DMSO-d6)δ6.47(d,J=43.7Hz,6H),3.59(s,3H),2.55–2.52(m,2H),2.45(t,J=7.0Hz,2H),1.91(s,3H)( Figure 3A ). 13 CNMR(151MHz,DMSO-d6)δ179.74,178.64,173.21,51.80,30.83,30.00,23.28( Figure 3B ). 195 PtNMR(129MHz,DMSO-d6)δ1230.55( Figure 3C ). ESI-HRMS (positive mode) m / z: C7H 17 [M+H] of Cl2N2O6Pt + Calculated value: 491.0111, measured value: 491.0081( Figure 3D The HCLP chromatogram of the obtained cis-Pt(IV)-3 showed a single peak, indicating the high purity of the complex ( Figure 3E ).
[0358] Example 1D
[0359] Synthesis of carPt(IV) (Pt(IV) complex of formula (IId))
[0360] The synthesis of carPt(IV) is summarized in Fig.59 (Scheme 4). The complex carPt(IV)-2OH was synthesized according to the reported method. 400 mg carPt(IV)-2OH was suspended in 3 mL acetic anhydride. The reaction mixture was stirred at room temperature overnight. Et2O was then added to the precipitate, and the product was collected, further washed with EtOH and Et2O, and dried in vacuo.1 HNMR(600MHz,DMSO-d6)δ6.57–6.13(m,6H),2.53–2.50(m,4H),1.91(s,6H),1.86–1.80(m,2H)( Figure 4A ). 13 CNMR(151MHz,DMSO-d6)δ177.76,176.70,55.98,31.66,23.00,16.20( Figure 4B ). 195 PtNMR(129MHz,DMSO-d6)δ1946.22( Figure 4C ). ESI-HRMS (positive mode) m / z: C 10 H 19 [M+H] of Cl2N2O8Pt + Calculated value: 490.0784, Measured value: 490.0784( Figure 4D The HCLP chromatogram of the obtained carPt(IV) showed a single peak, indicating the high purity of the complex ( Figure 4E ).
[0361] Example 1E
[0362] Synthesis of oxaPt(IV) (Pt(IV) complex of formula (IIe))
[0363] The synthesis of oxaPt(IV) is summarized in Fig.60 (Scheme 5). The complex oxaPt(IV)-2OH was synthesized according to the reported method. 400 mg of oxaPt(IV)-2OH was suspended in 3 mL of acetic anhydride. The reaction mixture was stirred at room temperature for 6 hours. Et2O was then added. The precipitate was collected by centrifugation, further washed with EtOH and Et2O, and finally dried in vacuo. 1 HNMR(600MHz,DMSO-d6)δ8.33(d,J=40.2Hz,4H),2.56(s,2H),2.10(d,J=12 .4Hz,2H),1.95(s,6H),1.54–1.46(m,2H),1.42(s,2H),1.21–1.10(m,2H)( Figure 5A ). 13 CNMR(151MHz,DMSO-d6)δ178.93,163.86,61.47,31.34,23.95,23.44( Figure 5B ). 195 PtNMR(129MHz,DMSO-d6)δ1615.06( Figure 5C ). C 12 H21 [M+H] of N2O8Pt + Calculated value: 510.0941, measured value: 510.0937( Figure 5D The HCLP chromatogram of the obtained oxaPt(IV) showed a single peak, indicating the high purity of the complex ( Figure 5E ).
[0364] Example 1F
[0365] Synthesis of transPt(IV) (Pt(IV) complex of formula (IIf))
[0366] The synthesis of transPt(IV) is summarized in Fig.61 (Scheme 6). 150 mg of reverse platinum was suspended in 8 mL of H2O. 1 mL of 30% H2O2 was added and the reaction mixture was stirred at room temperature for 24 hours. The solvent was removed in vacuo. The solid was washed with methanol and Et2O and dried. The solid was suspended in 1 mL of acetic anhydride and stirred at room temperature for 3 days. The desired product was directly purified by HPLC. 1 HNMR(600MHz,DMSO-d6)δ6.49–6.11(m,6H),1.92(s,6H)( Fig. 6A ). 13 CNMR(151MHz,DMSO-d6)δ178.59,23.44( Figure 6B ). 195 PtNMR(129MHz,DMSO-d6)δ1133.44( Figure 6C ). ESI-HRMS (positive mode) m / z: C4H 13 [M+H] of Cl2N2O4Pt + Calculated value: 418.9874, measured value: 418.9882( Fig.6D The HCLP chromatogram of the obtained transPt(IV) showed a single peak, indicating the high purity of the complex ( Fig. 6E ).
[0367] Example 1G
[0368] Synthesis of alkyne-Pt(IV) (Pt(IV) complex of formula (IV))
[0369] The synthesis of alkyne-Pt(IV) is summarized in Fig.62 (Scheme 7). As shown in the figure, the synthesis of alkyne-Pt(IV) involves the reaction of NH2-Pt(IV)-2Ac and compound L1, which are prepared as follows:
[0370] Synthesis of compound L1
[0371] 6-heptynoic acid (126 mg, 1 mmol) was dissolved in 2 mL DCM, followed by the addition of NHS (138 mg, 1.2 mmol) and then EDCI (287.5 mg, 1.5 mmol). The resulting reaction mixture was stirred at room temperature for 8 hours. After solvent evaporation, the residue was dissolved in EA, washed with brine, and then the solvent was evaporated in vacuo to give L1 as a pale yellow liquid, which solidified after standing. 1 HNMR (300 MHz, CHLOROFORM-d) δ 2.87 (d, J = 2.5 Hz, 4H), 2.68 (t, J = 7.4 Hz, 2H), 2.28 (td, J = 6.9, 2.7 Hz, 2H), 2.00 (t, J = 2.7 Hz, 1H), 1.91 (dt, J = 15.3, 7.4 Hz, 2H), 1.74–1.62 (m, 3H).
[0372] Synthesis of NH2-Pt(IV)-2Ac
[0373] As shown in Scheme 7, the synthesis of NH2-Pt(IV)-2Ac starts from the synthesis of compound 1. Specifically, 2-aminopropane-1,3-diol (900mg, 10mmol) and TEA (1.38mL, 10mmol) are dissolved in 5mL ethanol. Then a methanol (3mL) solution of di-tert-butyl dicarbonate (2.5mL, 10mmol) is added dropwise. The reaction mixture is stirred at room temperature for 5 hours, and the solvent is removed under reduced pressure. The crude product is washed with brine and extracted with EA to obtain compound 1 as a white powder.
[0374] Compound 1 was then converted to compound 2 as follows. TEA (2.1 mL, 15 mmol) was added to a solution of compound 1 (956 mg, 5 mmol), and tosyl chloride (2.85 g, 15 mmol) was then slowly added. The reaction mixture was stirred at room temperature for 2 hours. The mixture was extracted with DCM, washed with 1 M HCl and saturated NaHCO3. The organic phase was dried and purified with a column (PE (petroleum ether): EA (ethyl acetate) = 4: 1) to obtain compound 2 as a white powder. 1 HNMR (600MHz, chloroform-d) δ7.78 (d, J = 8.3 Hz, 4H), 7.38 (d, J = 8.1 Hz, 4H), 4.82 (d, J = 7.7 Hz, 1H), 4.09–4.02 (m, 4H), 2.49 (s, 6H), 1.42 (s, 9H).
[0375] Compound 2 is then converted to compound 3, which is then converted to compound 4 as follows. To a solution of compound 2 (1.6 g, 3.2 mmol) in 5 mL DMF, NaN (1.66 g, 25.6 mmol) is added. The reaction mixture is heated at 60 ° C overnight. Saturated NaHCO is then added to quench the reaction. After extraction with DCM, the organic phase is washed with brine and dried over Na2SO4. The solvent is evaporated under vacuum and purified with a column (PE: EA = 10: 1) to obtain compound 3 as a yellow oil. 1 H NMR (600 MHz, CHLOROFORM-d) δ 3.88 (d, J = 7.5 Hz, 1H), 3.48 (ddd, J = 65.9, 12.3, 5.4 Hz, 4H), 1.45 (s, 9H).
[0376] Afterwards, a suspension containing compound 3 (280 mg, 1.16 mmol) and Pd-C (10%) in a 50 mL round-bottom flask was connected to a hydrogen balloon, and deoxygenated methanol was carefully added. The resulting suspension was stirred at room temperature for 24 hours, after which the reaction was stopped by filtering the mixture through diatomaceous earth. The solvent was evaporated under reduced pressure to obtain compound 4 as a colorless oil. 1 HNMR (600 MHz, methanol-d4) δ 3.48 (ddd, J = 7.3, 5.4, 2.1 Hz, 1H), 3.31 (p, J = 1.6 Hz, 4H), 2.71 (dd, J = 13.2, 5.3 Hz, 2H), 2.59 (dd, J = 13.2, 7.4 Hz, 2H), 1.45 (s, 9H).
[0377] The synthesis of NH2-Pt (IV) -2Ac then proceeds to the synthesis step of compound 5. Specifically, potassium platinum chloride (208mg, 0.5mmol) is dissolved in 2mL water and stirred for 10min. Potassium iodide is dissolved in 2mL water and added to the mixture to obtain a purple solution, which is further stirred for 15min. Compound 4 (94.5mg, 0.5mmol) 2 aqueous solutions are added dropwise to the mixture to obtain a yellow precipitate, which is further stirred overnight in the dark at room temperature. The precipitate is then collected by centrifugation, and successively washed with water, ethanol and Et2O to obtain compound 5 in a brownish yellow precipitate.
[0378] Then compound 5 is converted into Boc-Pt (II), Boc-Pt (IV) -2OH, Boc-Pt (IV) -2Ac in sequence, and finally converted into NH2-Pt (IV) -2Ac. Specifically, compound 5 is suspended in water, and silver nitrate (153mg, 0.9mmol) dissolved in water is added to the slurry and stirred overnight at room temperature. Silver iodide precipitate is removed by centrifugation. And 2mL saturated sodium chloride solution is added to the filtrate, and stirred overnight in the dark at room temperature. Then the precipitate is collected and washed with water, ethanol and Et2O to obtain Boc-Pt (II) in white powder. 1 HNMR (600MHz, DMF-d7) δ7.06–6.99(m,1H),5.24(s,4H),3.82(d,J=8.7Hz,1H),2.84–2.78(m,2H),2.70(dp,J=12.6,4.0Hz,2H),1.40(s,9H).
[0379] Boc-Pt(II) (60 mg, 0.132 mmol) was then suspended in 500 μL of water, followed by addition of 50 μL of 30% H2O2 in an ice bath and stirred overnight at room temperature in the dark. The solid was washed with EtOH and Et2O and dried in vacuo to give Boc-Pt(IV)-2OH as a white solid. 1 HNMR (300MHz, DMSO-d6) δ7.20 (d, J = 7.8Hz, 1H), 6.50 (s, 4H), 2.34 (s, 4H), 1.39 (s, 9H).
[0380] Afterwards, Boc-Pt(IV)-2OH was suspended in acetic anhydride and stirred at room temperature overnight. The solvent was evaporated under vacuum and precipitated with Et2O. The solid was collected and washed with Et2O to obtain Boc-Pt(IV)-2Ac as a white powder. 1 HNMR(400MHz,DMSO-d6)δ8.23(s,2H),7.63(s,2H),6.98(d,J=6.8Hz,1H),3.72( d,J=8.7Hz,1H),2.47–2.24(m,4H),1.95(d,J=3.0Hz,6H),1.39(t,J=2.2Hz,9H).
[0381] Finally, 50 μL of 4M HCl in dioxane was added to a centrifuge tube containing 10 mg of Boc-Pt(IV)-2Ac cooled on ice. The mixture was stirred at room temperature for 2 hours. The solvent was then evaporated directly to obtain the crude product NH2-Pt(IV)-2Ac as a yellow solid. 1HNMR (300MHz, DMSO-d6) δ8.50 (s, 2H), 8.21 (s, 3H), 7.75–7.36 (m, 2H), 2.58 (d, J = 14.6 Hz, 4H), 1.96 (d, J = 8.9 Hz, 6H). ESI-HRMS (positive mode) m / z: C7H 17 [M+H] of Cl2N3O4Pt + Calculated value: 474.0297, measured value: 474.0304.
[0382] Synthesis of Alkyne-Pt(IV)
[0383] To a solution of NH2-Pt(IV)-2Ac (5 mg, 0.0105 mmol) in 50 μL DMF was added L1 (2.8 mg, 0.0126 mmol) and TEA (7.5 μL, 0.0432 mmol). The mixture was stirred at room temperature overnight. The solvent was evaporated in vacuo and purified by preparative HPLC to give alkyne-Pt(IV) as a white solid. 1 HNMR(600MHz,DMSO-d6)δ8.27(s,2H),7.99(d,J=7.1Hz,1H),7.58(s,2H),3.99–3.91(m,1H),2.84(t,J=2.7Hz,1H),2.44(dq,J=9.2, 5.2,4.6Hz,2H),2.30(dd,J=13.2,3.4Hz,2H),2.22(s,2H),2.02(td,J=7.4,2.7Hz,2H),1.95(d,J=4.3Hz,6H),1.66(t,J=7.4Hz,2H)( Fig. 7A ). 13 CNMR(151MHz,DMSO-d6)δ180.11,178.15,172.10,84.77,71.79,45.86,44.41,35.21,27.97,24.61,23.98,23.27,17.93( Figure 7B ). 195 PtNMR(129MHz,DMSO-d6):δ1156.52(s)( Figure 7C ). ESI-HRMS (positive mode) m / z: C 14 H 25 [M+H] of Cl2N3O5Pt + Calculated value: 582.0876, measured value: 582.0879( Fig.7D The HCLP chromatogram of the obtained alkyne-Pt(IV) showed a single peak, indicating the high purity of the complex ( Fig. 7E ).
[0384] Example 2A
[0385] Synthesis of Comparative Compound PC-1
[0386] The synthesis of PC-1 is summarized in Fig.63 (Scheme 8). 40 μL DMF was added to a solution of 225 mg (1 equivalent) of 6-heptynoic acid in 12 mL DCM. The mixture was cooled in an ice bath and 304.8 mg (1.3 equivalents) of oxalyl chloride was added. The mixture was stirred for 1 hour. 4-aminobenzophenone (352 mg, 1 equivalent) and TEA (0.4 mL) were added. The mixture was stirred at room temperature for 5 hours and the reaction was quenched with water. The organic phase was washed with brine and the product was purified by column chromatography (PE: EA = 3: 1). 1 HNMR(400MHz, chloroform-d)δ7.84–7.80(m,2H),7.80–7.74(m,2H),7.69–7.62(m,2H),7.61–7.55(m,1H),7.50–7.46(m,2H ),2.45(t,J=7.4Hz,2H),2.26(td,J=7.0,2.6Hz,2H),1.98(t,J=2.6Hz,1H),1.93–1.83(m,2H),1.65–1.61(m,2H)( Fig. 8A ). 13 CNMR (101MHz, chloroform-d)δ171.14,141.81,137.82,132.26,131.67,129.88,128.29,118.71,83.95,68.86,37.19,27.78,24.45,18.22( Figure 8B ). ESI-HRMS (positive mode) m / z: C 20 H 20 [M+H] of NO2 + Calculated value: 306.1489, measured value: 306.1468( Figure 8C The HCLP chromatogram of the obtained PC-1 showed a single peak, indicating the high purity of the compound ( Fig.8D ).
[0387] Example 2B
[0388] Synthesis of Comparative Compound PC-2
[0389] The synthesis of PC-2 is summarized in Fig.64(Scheme 9). HATU (228.1 mg, 1.2 equiv.), 4-[3-(trifluoromethyl)-3H-bis(aziridine-3-yl)benzylamine hydrochloride (113.2 mg, 0.9 equiv.) and DIEA (77.5 mg, 1.2 equiv.) were added to a solution of 6-heptynoic acid (63 mg, 1 equiv.) in DMF. The solution was stirred at room temperature overnight. The reaction was quenched with water. The organic phase was extracted with EA and further purified by column chromatography (PE:EA=3:1). 1 HNMR (400 MHz, chloroform-d) δ7.34–7.28 (m, 2H), 7.18–7.13 (m, 2H), 5.81 (s, 1H), 4.45 (d, J = 5.9 Hz, 2H), 2.30–2.23 (m, 2H), 2.23–2.19 (m, 2H), 1.94 (t, J = 2.7 Hz, 1H), 1.84–1.73 (m, 2H), 1.60–1.52 (m, 2H) ( Fig. 9A ). 13 CNMR (101MHz, chloroform-d)δ172.54,140.24,128.32,128.14,126.86,83.99,68.69,42.98,36.04,27.92,24.70,18.19( Fig. 9B ). ESI-HRMS (positive mode) m / z: C 16 H 17 [M+H] of F3N3O + Calculated value: 324.1319, measured value: 306.1269( Fig. 9C The HCLP chromatogram of the obtained PC-2 showed a single peak, indicating the high purity of the compound ( Fig.9D ).
[0390] Example 2C
[0391] Synthesis of the Reference Complex Alkyne-Pt(II)
[0392] The synthesis of alkyne-Pt(II) is summarized in Fig.65 (Scheme 10). Fig.65 As shown, the formation of alkyne-Pt(II) involves the reaction of compound NP and compound 11, which were prepared separately as follows.
[0393] Synthesis of compound NPs
[0394] As shown in the figure, the synthesis of compound NP starts with the step of synthesizing compound 6. Specifically, a solution of 1,3-diaminopropan-2-ol (900.1 mg, 10 mmol) and TEA (1.38 mL, 10 mmol) in methanol (3 mL) was heated to 45 ° C. Then a methanol (3 mL) solution of di-tert-butyl pyrocarbonate (20 mL, 80 mmol) was added dropwise. The reaction mixture was stirred at 45 ° C for 30 min. After stirring for another 2 hours at room temperature, the solvent was removed under reduced pressure. The crude product was extracted with EA to obtain compound 6 as a white powder. 1 HNMR (400 MHz, CHLOROFORM-d) δ 5.48 (t, J = 6.2 Hz, 2H), 3.67 (q, J = 5.3 Hz, 1H), 3.10 (t, J = 5.7 Hz, 4H), 1.36 (s, 18H).
[0395] Compound 6 was then converted into compounds 7 to 10 in sequence as follows. TEA (1.86 mL, 13.4 mmol) and toluenesulfonyl chloride (2.04 g, 10.74 mmol) were slowly added to a solution of compound 6 (2.62 g, 9 mmol) in DCM. The mixture was stirred at room temperature for 2 hours. The mixture was extracted with DCM, washed with 1 M HCl and saturated NaHCO3. The organic phase was dried and purified with a column (PE: EA = 5: 1) to give compound 7 as a white powder. 1 HNMR (400 MHz, CHLOROFORM-d) δ7.81 (d, J=8.0 Hz, 2H), 7.35 (d, J=8.1 Hz, 2H), 5.01 (s, 2H), 4.54 (s, 1H), 3.48–3.11 (m, 4H), 2.45 (s, 3H), 1.41 (s, 18H).
[0396] Then, NaN3 (1.2 g, 18.4 mmol) was added to a solution of compound 7 (2.06 g, 4.6 mmol) in 15 mL of anhydrous DMF. The mixture was heated at 60 ° C overnight. Saturated NaHCO3 was then added to quench the reaction. After extraction with DCM, the organic phase was washed with brine and dried over Na2SO4. The solvent was evaporated under vacuum and purified with a column (PE: EA = 10: 1) to give compound 8 as a white powder. 1 HNMR (400 MHz, CHLOROFORM-d) δ7.81 (d, J=8.0 Hz, 2H), 7.35 (d, J=8.1 Hz, 2H), 5.01 (s, 2H), 4.54 (s, 1H), 3.48–3.11 (m, 4H), 2.45 (s, 3H), 1.41 (s, 18H).
[0397] Afterwards, to a solution of compound 8 (1.15 g, 3.65 mmol) in 5 mL of MeOH, Pd-C (10%, 300 mg) was added and the mixture was hydrogenated with a balloon for 24 hours. The reaction mixture was filtered through celite and evaporated under reduced pressure, and purified by column (MeOH: DCM = 30: 1) to give the desired product (compound 9) as a clear oil, which solidified after standing. 1 HNMR (400 MHz, CHLOROFORM-d) δ 5.07 (s, 2H), 3.64 (p, J = 5.5 Hz, 1H), 3.36 (s, 2H), 3.14 (dd, J = 13.0, 6.7 Hz, 2H), 1.44 (s, 18H).
[0398] Compound 9 is further converted into compound 10 by reacting with compound L1. Specifically, L1 (50 mg, 0.329 mmol) is added to a solution of EDCI (75.8 mg, 0.394 mmol) in anhydrous DCM while stirring in an ice bath. An anhydrous DCM solution of compound 9 (114 mg, 0.394 mmol) is added dropwise. The reactant is then stirred for another 2 days at room temperature. The reactant is then quenched with H2O while stirring for 15 min. The mixture is then filtered, and the filtrate is washed with HCl (1 M) and saturated NaHCO3, and finally purified with a column (PE: EA = 3: 1) to obtain compound 10 as a white powder.
[0399] Finally, a 4M solution of HCl in dioxane was added to a flask containing compound 10 (60 mg, 0.14 mmol) cooled on ice. The mixture was stirred at room temperature for 2 hours. The solvent was then evaporated directly to give the product NP as a yellow solid. 1 HNMR(600MHz,DMSO-d6)δ8.23(t,J=6.5Hz,7H),4.20(dq,J=8.2,4.0,3.4Hz,1H),3.07–2.97(m,2H),2.91(ddd,J=13.3,7.9, 5.6Hz,2H),2.76(t,J=2.7Hz,1H),2.19(t,J=7.6Hz,2H),2.16(td,J=7.1,2.7Hz,2H),1.64–1.57(m,2H),1.48–1.41(m,2H). 13 CNMR (151 MHz, DMSO-d6) δ 173.53, 84.89, 71.74, 45.79, 35.22, 28.1, 24.18, 18.06. ESI-HRMS (positive mode) m / z: C 10 H 19 [M+H] of N3O +Calculated value: 198.1061, measured value: 198.1596.
[0400] Synthesis of compound 11
[0401] DMSO (106 μL, 1.5 mmol) was added to an aqueous solution of potassium platinum chloride (310 mg, 0.75 mmol) in 10 mL of water, and the solution was stirred at room temperature for 2 hours. The precipitate was filtered, washed with water, ethanol and ether, and dried overnight in vacuo. 1 HNMR(300MHz,DMF-d7)δ3.85(s,12H).
[0402] Synthesis of Alkyne-Pt(II)
[0403] DBU (29.9 μ L, 0.2 mmol) was added to a solution of NP (22.3 mg, 0.1 mmol) in anhydrous DMF, followed by compound 11 (42.2 mg, 0.1 mmol). The mixture solution was stirred at room temperature in the dark for 48 hours. Water was then added to the reaction mixture and the transparent brown solution was refrigerated overnight. The solid was separated by filtration, washed with water, ethanol, Et2O and dried in vacuo to obtain alkyne-Pt (II) as a yellow powder. 1 HNMR(600MHz,DMF-d7)δ7.96(d,J=7.8Hz,1H),5.25(d,J=42.0Hz,4H),4.19–4.11(m,1H),2.82(dt,J=9.3,3.5Hz ,2H),2.75(d,J=2.7Hz,1H),2.74–2.69(m,2H),2.25–2.19(m,4H),1.68(p,J=7.5Hz,2H),1.51(p,J=7.2Hz,2H)( Fig. 10A ). 13 CNMR(151MHz,DMF-d7)δ173.32,85.69,71.72,48.77,48.12,26.08,19.21( Fig. 10B ). 195 PtNMR(129MHz,DMF-d7):δ-2287.34(s)( Fig. 10C ). ESI-HRMS (positive mode) m / z: C 10 H 19 [M+H] of Cl2N3OPt + Calculated value: 464.0608, measured value: 464.0613( Fig. 10D ).
[0404] Example 3
[0405] Structural characterization
[0406] Three representative Pt(II) anticancer drugs (including cisplatin, carboplatin and oxaliplatin and trans-platinum used clinically worldwide) were selected as the equatorial core of the Pt(IV) structure of the present invention. Molecular scaffolds lacking strong absorption at 365nm, particularly acetic acid, succinic acid and succinate, were selected as harmless axial ligands.
[0407] In this example, six Pt(IV) complexes ( Fig.11 ). The results were analyzed by electrospray ionization high-resolution mass spectrometry (ESI-HRMS) and multinuclear NMR spectroscopy ( 1 H. 13 C and 195 The synthesized complex was fully characterized and its purity was determined by analytical reverse phase HPLC (RP-HPLC, 254 nm; >95%). Figures 1A-1E , 2A-2E, 3A-3E, 4A-4E, 5A-5E and 6A-6E).
[0408] Example 4
[0409] Photolysis properties
[0410] The photolysis characteristics of Pt(IV) complex in water were studied by HPLC. Fig.12 ) at about 9.8mW / cm 2 When irradiated with a power density of 100 μg / min, the peak heights of all Pt(IV) complexes in the HPLC chromatogram decreased significantly ( Figures 13A-13B , 14-18), and the appearance of various new species, indicating the rapid photolysis of the Pt(IV) complex. In contrast, the corresponding Pt(II) complexes are relatively resistant to photolysis; for example, 75% of cisplatin and 99% of oxaliplatin remain stable under the experimental conditions ( Fig.19 and 20A -20D). Similar photolysis characteristics were observed for transPt and transPt(IV) ( Figure 14-19 The formation of the Pt(II) counterpart ( Pt(IV) complex with cis geometry) was confirmed using HPLC and ESI-HRMS. Fig. 13B and 14 -18).
[0411] It is believed that the photolysis of Pt(IV) complexes may involve a free radical formation mechanism. Therefore, the photolysis mechanism of Pt(IV) complexes was studied. First, the generation of free radicals after complex photolysis was determined by methylene blue (MB) degradation experiments. Figures 21A-21E , 22A-22C, 23A-23C, and 24A-24C, in the Pt(IV) complex treated group, MB was completely degraded after 10 min of irradiation. In contrast, MB remained intact in the Pt(II) complex treated samples. These results suggest that the Pt(IV) complex, rather than the Pt(II) counterpart, generates reactive radical species upon photolysis. Similar effects were observed for transPt and transPt(IV) ( Fig. 24B and 24C ), which means that the oxidation state rather than the coordination geometry determines the ability to generate reactive radical species.
[0412] To further explore the photolysis mechanism, free radical spin trapping experiments were performed. Cis-Pt(IV)-1 was used as an exemplary complex for the experiments. Typically, the photolysis of the cis-Pt(IV)-1 complex was monitored in the presence of two common spin traps: 5,5-dimethyl-1-pyrroline N-oxide (DMPO) and (2,2,6,6-tetramethylpiperidin-1-yl)oxy (TEMPO). Fig.25A and 25B As shown, different new species were observed in the presence of the radical spin trap after 10 min of irradiation. In contrast, the radical spin trap itself was stable upon irradiation, and free cisPt(IV)-1 as well as its mixture with the radical spin trap remained intact for about 30 min ( Figures 25C-25D and 26A–26C), indicating that the radical species were formed due to the photolysis of cisPt(IV)-1.
[0413] Notably, upon irradiation, a new peak appeared at 8.9 min in the HPLC chromatogram of the mixture of DMPO and cisPt(IV)-1, which was subsequently separated and characterized as the spin adduct of DMPO with acetate ion ligand (DMPO-Ac), thus demonstrating the formation of acetate radicals ( Fig.25A and 27 -28). The platinum-containing spin adducts of TEMPO were further identified by the characteristic isotope pattern of platinum via ESI-HRMS. Upon irradiation, two spin adducts of TEMPO with platinum, [Pt(NH3)2(TEMPO)Cl] and [Pt(NH3)2(TEMPO)OH], were observed in the cisPt(IV)-1 solution, indicating the formation of the Pt(I) radical ( Figures 29A-29D In contrast, these spin adduct products with platinum were not observed in the Pt(II) treated group ( Figure 27-28 and 29A-29D), suggesting that these radical species originate directly from the photolysis of the Pt(IV) complex rather than the resulting Pt(II) counterpart.
[0414] To reveal more information about the reactive radical species, electron paramagnetic resonance (EPR) measurements were performed using DMPO and (2,2,6,6-tetramethylpiperidinyl)oxy (TEMP) as radical spin traps. Fig.30 As shown, upon irradiation, a seven-line EPR spectrum of DMPOX appeared in the cisPt(IV)-1 treated group, which was identified as a derivative of DMPO oxidized by chlorine radicals, indicating the presence of chlorine radicals during photolysis. The formation of chlorine radicals was then verified using the N,N-diethyl-p-phenylenediamine (DPD) standard method. Upon irradiation, an absorption spectrum peak at 515 nm was observed in the cisPt(IV)-1 treated group, which is known to correspond to Würster dye (a magenta compound formed by the reaction between colorless DPD and free chlorine), but was not observed in the cisplatin treated group ( Figures 31A-31C ), confirming the generation of chlorine radicals after photolysis. In addition, the triplet signal corresponding to the adduct of TEMP and singlet oxygen (TEMPO) disappeared in the cisPt(IV)-1 solution upon irradiation ( Fig.32 ). Given that free radical species quench TEMPO, this further suggests that free radical species are generated during the photolysis of the Pt(IV) complex.
[0415] Given the fact that cisPt(IV)-1 generates reactive radical species during photolysis, it is believed that reactive oxygen species (ROS) may be further generated in the presence of oxygen and water. As a carrier, 2'7'-dichlorofluorescein diacetate (DCFH-DA) was used as a ROS probe to detect any ROS generated upon photolysis of cisPt(IV)-1. Fig.33 As shown, the cisPt(IV)-1 solution exhibited a significantly increased fluorescence intensity upon irradiation (compared to the sample treated with cisplatin), indicating the formation of ROS after photolysis of cisPt(IV)-1. These results were further confirmed by using two colorimetric hydroxyl radical probes, 3,5,3',5'-tetramethylbenzidine (TMB) and o-phenylenediamine (OPD). Figures 31A-31C As shown in Figure 2, in the cisPt(IV)-1 treated group but not in the cisplatin treated group, characteristic absorption peaks at 652 nm and 440 nm were observed upon irradiation, which are the products of TMB (oxTMB) and OPD (oxOPD) oxidation by hydroxyl radicals, respectively. It should be noted that under hypoxic conditions, less ROS were generated than under normoxic conditions, which was reflected in the decreased fluorescence intensity of DCFH-DA ( Fig.34A ) and different patterns of photolysis products ( Fig.34B ), which indicates that oxygen is indeed involved in the photolysis process of cisPt(IV)-1.
[0416] Unexpectedly, it was found that in a saturated aqueous solution of cisPt(IV)-1 containing DMPO, a yellow precipitate ( Fig.35A ), which was confirmed to be cisplatin ( Figures 35B-35D ). It is believed that due to the limited solubility of cisplatin in water, free radical spin trapping may increase the yield of cisplatin and subsequently lead to precipitation. Therefore, the yield of cisplatin upon photolysis of cisPt(IV)-1 was monitored by LC-HRMS in the presence and absence of DMPO or TEMPO. It was found that the presence of these free radical spin traps increased the yield of cisplatin in a concentration-dependent manner ( Fig.36 , 37A -37B and 38A-38C), and no significant difference in the photolysis rate was observed after the addition of radical spin trapping ( Fig.39 and 40A -40C). Based on these observations, it is believed that cisplatin is one of the photolysis products of cisPt(IV)-1, which is attacked by reactive radical species generated during the photolysis process. In the presence of radical spin trapping, these radical species are quenched, resulting in a higher cisplatin yield.
[0417] Based on the above, it is believed that the photolysis of cisPt(IV)-1 may mainly follow Fig.41 The mechanism shown. Specifically, upon irradiation, cisPt(IV)-1 is excited to a transition state via ligand-metal charge transfer (LMCT). Each acetate ion ligand then donates an electron to the Pt(IV) center, resulting in homolytic cleavage of the Pt-O bond and subsequent reductive elimination, producing cisplatin and acetate radicals. The latter further produces ROS in the presence of oxygen and water. These reactive radical species then attack cisplatin, producing various active platinum species and chlorine radicals.
[0418] Example 5
[0419] Photoinitiation of polymerization and antimicrobial properties
[0420] Considering the generation of free radical species during the photolysis of the Pt(IV) complex, it is believed that these free radical species could potentially initiate the polymerization of monomers to form a macromolecular hydrogel network ( Fig.42 In order to test the potential of Pt(IV) complexes as photoinitiators, gelation experiments with acrylamide were performed. Fig.43 As shown, in samples treated with cisPt(IV)-1 instead of cisplatin, the liquid solution transformed into a solid-like gel (Pt-gel) upon irradiation. Scanning electron microscopy (SEM) analysis showed that the solid-like gel had a porous network and a uniform microstructure ( Fig.44 ).
[0421] To further examine the homogeneity of the Pt-gel, specific protein markers, cell lysates, and bovine serum albumin (BSA) were subsequently subjected to gel electrophoresis using the Pt-gel. Fig.45A ) similarly, protein samples were well separated in Pt-gel ( Fig.45B ), which indicates the ability of Pt(IV) species to act as photoinitiators to induce homogeneous polymer photopolymerization.
[0422] It is understood that low concentrations of cisplatin can inhibit cell division and induce filamentous growth of bacteria such as Escherichia coli. Considering that the Pt(IV) complex in this work can act as a photoinitiator during gel formation, it is believed that after Pt-gel formation, platinum can be retained in the gel, so Pt-gel can exhibit antibacterial activity. In fact, as shown in the release curve of platinum from the Pt-gel scaffold ( Fig.46 ), more than 75% of the photolytically active Pt species are likely captured in the Pt-gel network via cross-linking.
[0423] The antibacterial properties of Pt-gel against Escherichia coli (DH5α), a typical pathogenic Gram-negative bacteria, were then evaluated using the spread plate method. Control experiments using PBS, cisplatin, and photocrosslinked gels prepared using I2959 (a common photoinitiator) were also performed. Many bacterial colonies can be observed on agar plates treated with PBS and I2959-gel. In sharp contrast, there were no visible colony forming units (CFU) on agar plates treated with Pt-gel after 4 hours ( Fig.47 To further confirm the antibacterial activity of Pt-gel, E. coli was incubated in lysogeny broth with or without Pt-gel, and the optical density was measured at different time points. 600 The values increased with the increase of incubation time and remained stable after 8 h, which was consistent with the growth pattern of normal bacteria. In contrast, in the samples treated with Pt-gel, the OD 600 The values remained low and unchanged, indicating that Pt-gel has excellent antibacterial properties ( Fig.48 ).
[0424] Example 6
[0425] Photo-crosslinking properties
[0426] When considering photoinduced reactive Pt species, including platinum radicals and Pt(II) species generated from Pt(IV) complexes in this work, which can potentially react with various bionucleophiles (i.e., Pt(IV) complexes can be considered photocaged electrophiles), it is believed that Pt(IV) complexes can be used as photocrosslinkers and / or photoreactive biomolecule labeling agents.
[0427] The reactivity of Pt(IV) complexes with individual model amino acids upon photolysis was studied. Figures 49A-49D As shown, Pt-amino acid adducts were observed for all amino acids tested. The binding efficiency of the Pt(IV) complexes to bovine serum albumin (BSA) was then examined using ICP-OES. In the absence of irradiation, both Pt(II) and Pt(IV) species showed limited ability to bind to proteins; less than 10% of the platinum complexes were bound to BSA, and the Pt(IV) complex exhibited a slightly lower binding rate than the Pt(II) counterpart due to its greater kinetic inertness. In contrast, after irradiation, a significant increase in binding rate was observed in the Pt(IV)-treated samples. In particular, cisPt(IV)-1 and carPt(IV) showed more than 80% of the platinum complexes bound to BSA, indicating that the photolyzed platinum products can effectively (photo)crosslink with proteins ( Fig.50 ).
[0428] Considering the above-mentioned efficient protein photocrosslinking properties of Pt(IV) complexes, it is believed that Pt(IV) species can act as photocrosslinkers to directly produce gelatin hydrogels ( Fig.51 To confirm that the Pt(IV) complex can achieve this effect, gelation experiments using cisplatin and cisPt(IV)-1 were performed. Fig.52 As shown, upon irradiation, the formation of gelatin hydrogels could be clearly observed in the cisPt(IV)-1-treated samples but not in the cisplatin-treated samples, indicating that the Pt(IV) complex can be used as a photocrosslinker for the direct fabrication of gelatin hydrogel scaffolds.
[0429] Example 7
[0430] Light marking characteristics
[0431] In order to further study the photocrosslinking and photolabeling properties of the Pt(IV) complex of the present invention, a novel photocrosslinker alkyne-Pt(IV) was designed and synthesized, which is based on cisPt(IV)-1 and contains a bioorthogonal handle alkyne ( Figures 7A-7E Upon photolysis, the reactive platinum species can immediately cross-link to the protein, allowing for the subsequent introduction of reporter molecules such as fluorescent groups ( Fig.53A ). BSA was then used to evaluate the labeling efficiency of alkyne-Pt(IV). Common phenol- and diazirine-based photocrosslinkers PC-1 and PC-2 were synthesized for comparison ( Figures 8A-8D , 9A-9D and 53B). The Pt(II) counterpart alkyne-Pt(II) was also synthesized as a control ( Fig.53B and 10A -10D).
[0432] Without irradiation, all probes exhibited low labeling efficiency, with alkyne-Pt(II) showing higher labeling efficiency than alkyne-Pt(IV). In sharp contrast, under irradiation, a significant enhancement of fluorescence was observed in samples treated with alkyne-Pt(IV). The fluorescence intensity of alkyne-Pt(IV) was 1.7 times that of the organic probes PC-1 and PC-2 ( Fig.54A and 54B ). In addition, to examine the kinetics of the photocrosslinking process, pulse-chase labeling of the proteins was performed by switching the light on and off. Light dependence of the protein labeling was observed, with a clear increase in fluorescence intensity after each light pulse, indicating the instantaneous nature of the crosslinking process and the temporal specificity afforded by the use of external light ( Fig.55A and 55B ).
[0433] The present invention is presented by way of example only, and various other modifications and / or alterations to the described embodiments may be made by those skilled in the art without departing from the scope of the present invention as specified in the appended claims.
Claims
1. A platinum-based adduct comprising a substrate to which is attached a photolyzed active platinum species, the photolyzed active platinum species being generated from a platinum (IV) complex having a structure of formula (Ia): wherein X, X', Y, Y', R and R' are electron donor ligands; and n is zero, any positive charge or a negative charge.
2. The platinum-based adduct of claim 1, wherein at least one of the electron donor ligands comprises one or more of a nitrogen-containing ligand, an oxygen-containing ligand, a phosphorus-containing ligand, a sulfur-containing ligand, or a halogen-containing ligand.
3. The platinum-based adduct of claim 1, wherein the photolyzed active platinum species comprises platinum (I) radicals.
4. The platinum-based adduct of claim 1, wherein the platinum (IV) complex has the structure of formula (Ib): in: X, X', Y and Y' are independently selected from the group consisting of ammonia, halides, oxalates, diamines, dicarboxylates and glycolates, R1 and R2 are independently selected from the group consisting of a linear or branched C1-C4 alkyl chain, a carboxyl group, and a carboxylate-containing group; and n is zero charge.
5. The platinum-based adduct of claim 4, wherein X and X' are linked to form a first bidentate ligand.
6. The platinum-based adduct of claim 4, wherein Y and Y' are linked to form a second bidentate ligand.
7. The platinum-based adduct of claim 1, wherein the substrate is hydrogel-based or biomolecule-based.
8. The platinum-based adduct of claim 4, wherein R1 and R2 are independently selected from the group consisting of: -CH3, -CH2CH3, -CH2CH2CH3, -CH2COOH, -CH2CH2COOH, -CH2COOCH3, -CH2CH2COOCH3 and -CH2COOCH2CH3.
9. The platinum-based adduct of claim 6, wherein X and X' are ammonia and / or chloride; the second bidentate ligand is a diamine; R1 and R2 are -CH3, -CH2CH2COOH or -CH2CH2COOCH3; and n is zero charge.
10. The platinum-based adduct of claim 5, wherein Y and Y' are ammonia and / or chloride, the first bidentate ligand is cyclobutanedicarboxylate and / or oxalate, R1 and R2 are -CH3, -CH2CH2COOH or -CH2CH2COOCH3; and n is zero charge.
11. The platinum-based adduct of claim 4, wherein the platinum (IV) complex has a structure of Formula (IIa), Formula (IIb), Formula (IIc), Formula (IId), Formula (IIe) or Formula (IIf):
12. The platinum-based adduct of claim 11, wherein the platinum (IV) complex of formula (IIa) generates one or more of acetate radicals, cisplatin, chloride radicals, ROS, and the photolyzed active platinum species.
13. The platinum-based adduct of claim 11, wherein the chemical structure of the platinum (IV) complex remains unchanged for at least 30 min in the absence of radiation.
14. The platinum-based adduct of claim 7, wherein the hydrogel substrate comprises any one of polyacrylamide or gelatin.
15. The platinum-based adduct according to claim 7, wherein the biomolecule substrate comprises any one of an amino acid or a polypeptide.
16. The platinum-based adduct of claim 14, wherein the hydrogel substrate comprises any one of 10% acrylamide / bisacrylamide (29:1) and 5% gelatin.
17. The platinum-based adduct of claim 15, wherein the amino acid is selected from cysteine, methionine, tryptophan and tyrosine, and the polypeptide is BSA.
18. The platinum-based adduct of claim 4, wherein the platinum (IV) complex further comprises a functional moiety attached to the platinum (IV) complex for functionalizing the platinum-based adduct.
19. The platinum-based adduct of claim 18, wherein the platinum (IV) complex has the structure of formula (IIIa): in: X, X', Y, Y', R and R' are as defined above; L is a linking group; F is the functional moiety for functionalizing the platinum-based adduct; and n' is zero, any positive charge, or any negative charge.
20. The platinum-based adduct of claim 19, wherein the functional moiety has a reactive group that is complementary to a reactive group of a fluorescent reporter unit.
21. The platinum-based adduct of claim 20, wherein the platinum (IV) complex has the structure of formula (IIIb): in: m is 1-6; F is the functional moiety which is a bioorthogonal group selected from the group consisting of azide, terminal alkyne, activated cyclooctyne and tetrazine; and n' is zero charge.
22. The platinum-based adduct of claim 21, wherein the platinum (IV) complex has the structure of formula (IV):
23. A photoinitiator for hydrogelation comprising a photolyzed active platinum species generated from a platinum (IV) complex having the structure of formula (Ia): wherein X, X', Y, Y', R and R' are electron donor ligands; and n is zero, any positive charge or a negative charge.
24. The photoinitiator of claim 23, wherein the platinum (IV) complex has the structure of formula (Ib): in: X, X', Y and Y' are independently selected from the group consisting of ammonia, halides, oxalates, diamines, dicarboxylates and glycolates, R1 and R2 are independently selected from the group consisting of a linear or branched C1-C4 alkyl chain, a carboxyl group, and a carboxylate-containing group; and n is zero charge.
25. The photoinitiator of claim 23, wherein 75% of the photolyzed active platinum species remain after exposure to radiation.
26. The photoinitiator of claim 24, wherein the platinum (IV) complex has the structure of formula (IIa):
27. A photocrosslinker for hydrogelation or protein labeling, comprising a photolyzed active platinum species generated from a platinum (IV) complex having a structure of formula (Ia) or formula (IIIa): in: X, X', Y, Y', R and R' are electron donor ligands; L is a linking group; F is a functional moiety for protein labeling; and n and n' are each independently zero, any positive charge, or any negative charge.
28. The photocrosslinker of claim 27, wherein the platinum (IV) complex has the structure of formula (Ib): in: X, X', Y and Y' are independently selected from the group consisting of ammonia, halides, oxalates, diamines, dicarboxylates and glycolates, R1 and R2 are independently selected from the group consisting of a linear or branched C1-C4 alkyl chain, a carboxyl group, and a carboxylate-containing group; and n is zero charge.
29. The photocrosslinker of claim 28, wherein the platinum (IV) complex has the structure of formula (IIa):
30. The photocrosslinker of claim 27, wherein the platinum (IV) complex has a structure of formula (IIIb): in: m is 1-6; F is the functional moiety which is a bioorthogonal group selected from the group consisting of azide, terminal alkyne, activated cyclooctyne and tetrazine; and n' is zero charge.
31. The photocrosslinker of claim 30, wherein the platinum (IV) complex has the structure of formula (IV):
32. An antimicrobial platinum-based adduct comprising a substrate to which is attached a photolytically active platinum species generated from a platinum (IV) complex having the structure of formula (IIa):
33. The antibacterial platinum-based adduct of claim 32, wherein the substrate comprises polyacrylamide and has antibacterial activity against Escherichia coli (DH5α).
34. A method for preparing the platinum-based adduct as claimed in claim 1, comprising the following steps: providing a solution mixture comprising a hydrogel precursor or a biomolecule and a platinum (IV) complex having a structure of formula (Ia); as well as Radiation of an amount and wavelength effective to activate the platinum (IV) complex is applied to the solution mixture to form a photolyzed active platinum species comprising platinum (I) radicals, which reacts with the hydrogel precursor or the biomolecule to form the platinum-based adduct.
35. The method of claim 34, wherein the radiation is UV radiation.
36. The method of claim 35, wherein the UV radiation has a wavelength of 360 nm to 370 nm.
37. The method of claim 36, wherein the 2 Up to 10mW / cm 2 The UV radiation is applied at a power density of 100 Å.
